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NOVEL FOOD INGREDIENTS: FOOD SAFETY
LAW, ANIMAL TESTING, AND CONSUMER
PERSPECTIVES
TAIMIE BRYANT*
In recent years, some major food companies have publicly stated that they
will no longer test their product ingredients on animals. Yet despite the
availability of more reliably predictive non-animal toxicity tests, some
companies continue testing novel food ingredients on animals. This Article uses
the lens of a particular innovative plant-based food company’s decision to test
a novel food ingredient on animals as a means of considering more generally
whether any food producer has rational legal reasons for testing on animals.
The Article explores FDA requirements, consumer food safety litigation, and
judicial evaluation of animal test data, all of which align with lack of necessity
to use animal testing to protect consumer safety. The Article presents reasons
to change to more reliable non-animal tests, describes results of recent
research on consumer perspectives, and identifies several avenues for reducing
animal testing while improving food safety.
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INTRODUCTION
Although protein alternatives to meat consumption have been in existence
somewhere in the world since the year 965,1 recognition of their importance has
accelerated as people grow more conscious of negative animal welfare,
environmental, and human health impacts of consuming animal-based foods.2
Since the 1960s and ’70s, Americans have had ready access to manufactured
alternatives to meat,3 but it was not until 2015 that near-perfect replicas of
hamburgers began emerging on the scene. In 2015, Beyond Meat (Beyond)
introduced the Beyond Burger,4 followed closely by introduction of the
Impossible Burger by Impossible Foods (Impossible) in 2016.5 Both of these
companies have developed burgers with the “mouth feel,” flavor, aroma, and
“bleeding” properties of beef hamburgers.6 They believe that the development
1. WILLIAM SHURTLEFF & AKIKO AOYAGI, HISTORY OF MEAT ALTERNATIVES (965 CE TO
2014): EXTENSIVELY ANNOTATED BIBLIOGRAPHY AND SOURCEBOOK 5 (2014).
2. Plant-based Meat Market by Source (Soy, Wheat, Blends, Pea), Product (Burger Patties,
Strips & Nuggets, Sausages, Meatballs), Type (Beef, Chicken, Pork, Fish), Distribution Channel,
Storage and Region - Global Forecast to 2027, MKTS. & MKTS. (July 2022),
https://www.marketsandmarkets.com/Market-Reports/plant-based-meat-market-44922705.html
[https://perma.cc/4EVB-Q8D6]; Emily Monaco, How Meat Eaters, not Vegans, are Driving the PlantBased Foods Boom, According to Industry Experts, BUS. INSIDER (Sept. 21, 2020),
https://www.businessinsider.com/plant-based-meats-flexitarians-vegetarians-vegans-marketrevolution-2020-9 [https://perma.cc/DK59-FDRT]; Fatma Boukid, Plant-Based Meat Analogues:
From Niche to Mainstream, EUROPEAN FOOD RSCH. & TECH., Oct. 2021, at 298
https://link.springer.com/article/10.1007/s00217-020-03630-9 [https://perma.cc/U5R5-KE2X].
3. SHURTLEFF & AOYAGI, supra note 1, at 8–9.
4. The Beyond & the Beast: A Tale of Two Burgers, BEYOND MEAT: BLOG (Dec. 21, 2016),
https://www.beyondmeat.com/en-US/whats-new/the-beyond-the-beast-a-tale-of-two-burgers
[https://perma.cc/3238-LGRT].
5. Impossible
Foods
Inc.,
Impossible
Foods,
https://assets.ctfassets.net/hhv516v5f7sj/1sCviuUjx24iZXOOJNMiFn/41d41396647482fd4a5d45fb6
0915b1f/CEL_IMP_CompanyOverview_English_210730.pdf [https://perma.cc/ZTM9-5GE2] (last
visited Nov. 15, 2022) (company overview).
6. See Our Products, BEYOND MEAT, https://www.beyondmeat.com/en-CA/products/
[https://perma.cc/6X8Y-XTRW] (“Imagine a world where we’ve taken the animal off the table, while
still delivering the meaty, plant-based, better-for-you meals you crave. That world is this one, and those
meals are Beyond.”); Our Mission, BEYOND MEAT, https://www.beyondmeat.com/en-US/mission/
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of plant-based meat alternatives can help arrest climate deterioration by
reducing the significantly negative impact of meat consumption.7 Both target
meat-eaters unlikely to switch to plant-based meat alternatives unless those
alternatives perfectly replicate the experience of eating meat.8 These companies
have generally succeeded in creating such substitutes; it is difficult to
differentiate these plant-based burgers from beef-based burgers.9
[https://perma.cc/5NQY-7UKQ] (“We combine expert innovation with simple, non-GMO ingredients
to deliver the meaty experience you crave without the compromise.”); Impossible Foods Inc.,
Impossible Foods Introduces Impossible Burger at Momofuku Nishi, CISION PR NEWSWIRE (July 26,
2016), https://www.prnewswire.com/news-releases/impossible-foods-introduces-impossible-burgerat-momofuku-nishi-300303881.html [https://perma.cc/W3RW-Q3JU] (“The Impossible Burger looks,
cooks, smells, sizzles, and tastes like conventional ground beef but is made entirely from plants.
Among the breakthroughs that make the Impossible Burger unique is the discovery that a molecule
called ‘heme’ is the magic ingredient that makes meat look, cook and taste gloriously meaty.”).
7. Tad Friend, Can a Burger Help Solve Climate Change?, NEW YORKER (Sept. 23, 2019),
https://www.newyorker.com/magazine/2019/09/30/can-a-burger-help-solve-climate-change
[https://perma.cc/2F7W-LABH] (“The use of animals in food production is by far the most destructive
technology on earth. ‘We see our mission as the last chance to save the planet from environmental
catastrophe’. . . . [Brown] understood that the facts [of climate change and the large role of meat
consumption] didn’t compel people as strongly as their craving for meat, and that shame was
counterproductive. So he’d use the power of the free market to disseminate a better, cheaper
replacement. And, because sixty per cent of America’s beef gets ground up, he’d start with burgers.”)
(quoting Pat Brown); David Gelles, The “Hedonistic Altruism” of Plant-Based Meat, N.Y. TIMES
(Aug. 27, 2021), www.nytimes.com/2021/08/27/business/ethan-brown-beyond-meat-corneroffice.html [https://perma.cc/7397-8UTP] (“Ethan Brown contends there are several main benefits to
consuming plant-based foods instead of animal meat. It leads to fewer greenhouse gas emissions, it
consumes fewer natural resources and it is better for human health . . . . ‘You can focus on one thing,
which is to simply change the protein, and have a real impact on four global issues that fascinate me:
the climate, natural resources, animal welfare and human health.’ ”) (quoting Ethan Brown).
8. Andrea Kramar & Catherine Clifford, How Beyond Meat Became a $550 Million Brand,
Winning Over Meat-Eaters With a Vegan Burger That “Bleeds”, CNBC (Jan. 22, 2019),
www.cnbc.com/2019/01/21/how-bill-gates-backed-vegan-beyond-meat-is-winning-over-meateaters.html [https://perma.cc/47SS-LL2M] (“[W]e’re reaching mainstream consumers that are
interested in healthier forms of meat’ . . . . Brown says the company found that 93 percent of the
consumers in conventional grocery stores that are buying a Beyond Meat product are also putting
animal meat [in] their basket. ‘So they’re buying not only plant based meat, but they’re buying animal
meat and that’s a really important breakthrough for us,’ Brown tells CNBC Make It.”) (quoting Patrick
Brown); Dr. Pat Brown, CEO, Impossible Foods, CNBC (Oct. 29, 2019), https://www.cnbc.com/drpat-brown-transcript/ [https://perma.cc/6WLJ-MCHM] (“In terms of who the actual consumers of our
products are intended to be, it’s not vegetarians. We are entirely devoted to making delicious products
for meat lovers. We are all about pleasing meat lovers. I’m vegetarian. I’ve been vegetarian for most
of my life. I love vegetarians. But we’re not here to serve vegetarians.”).
9. Mariana Lamas, How Scientists Make Plant-Based Foods Taste and Look More Like Meat,
CONVERSATION (May 5, 2021), https://theconversation.com/how-scientists-make-plant-based-foodstaste-and-look-more-like-meat-156839 [https://perma.cc/ZJ3D-B5VF] (“Burger King Sweden created
menu item where customers would have a 50-50 chance of getting a meat burger or a plant-based one.
To find out, they had to scan the burger box in Burger King’s app. The results: 44 per cent guessed
wrong—customers couldn’t tell the difference.”).
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If it is true that these alternatives will drastically reduce consumption of
beef, they would provide a significant benefit to human and nonhuman
occupants of the earth because beef, the second most popular source of animal
protein, has a considerably more damaging environmental footprint than other
animal-based foods.10 According to research reported in 2014, “[beef] causes
about one-fifth of global greenhouse gas emissions, and is the key land user and
source of water pollution by nutrient overabundance. It also competes with
biodiversity, and promotes species extinctions.”11 Of particular importance to
those who care about animal welfare, both companies argue that these burgers
will significantly reduce consumption of cows,12 whose lives and deaths are
filled with tremendous human-inflicted suffering.13
10. Gidon Eshel, Alon Shepon, Tamar Makov & Ron Milo, Land, Irrigation Water, Greenhouse
Gas, and Reactive Nitrogen Burdens of Meat, Eggs, and Dairy Production in the United States, 111
PROC. NAT’L ACAD. SCI. U.S. AM. 11996, 11996 (2014) https://DOI.ORG/10.1073/PNAS/140218331
[https://perma.cc/M7DX-W4GM] (“Beef, the least efficient against all four metrics [extent of land use,
amount of necessary irrigation water, extent of greenhouse gas emission, and reactive nitrogen burdens
from animal waste] is the second most popular animal category in the mean US diet, accounting for
7% of all consumed calories. Interestingly, dairy, by far the most popular category, is not more efficient
than pork, poultry, or eggs.”); See also Oliver Milman, Meat Accounts for Nearly 60% of All
Greenhouse Gases from Food Production, Study Finds, THE GUARDIAN (Sept. 13, 2021),
https://www.theguardian.com/environment/2021/sep/13/meat-greenhouses-gases-food-productionstudy [https://perma.cc/Z22B-G8QK] (“The global production of food is responsible for a third of all
planet-heating gases emitted by human activity, with the use of animals for meat causing twice the
pollution of producing plant-based foods, a major new study has found.”) (citing Xiaoming Xu, Prateek
Sharma, Shijie Shu, Tzu-Shun Lin, Philippe Ciais, Francesco N. Tubiello, Pete Smith, Nelson
Campbell & Atul K. Jain, Global Greenhouse Gas Emissions from Animal-Based Foods Are Twice
Those of Plant-Based Foods, 2 NATURE FOOD 724 (2021) (finding that beef accounts for 25% of
greenhouse
gas
emissions
attributable
to
animal-based
commodities)
https://www.nature.com/articles/s43016-021-00358-x [https://perma.cc/Z355-JTV8])).
11. Eshel, Shepon, Makov & Milo, supra note 10, at 11996; see also Joseph Poore & Thomas
Nemecek, Reducing Food’s Environmental Impacts Through Producers and Consumers, 360 SCIENCE
987 (2018) https://www.science.org/doi/10.1126/science.aaq0216 [https://perma.cc/GM89-7T6W]
(including documentation of high impact of beef).
12. Patrick Greenfield, “Let’s Get Rid of Friggin’ Cows” Says Creator of Plant-Based “Bleeding
Burger,” GUARDIAN (Jan. 8, 2021), https://www.theguardian.com/environment/2021/jan/08/lets-getrid-of-friggin-cows-why-one-food-ceo-says-its-game-over-for-meat-aoe
[https://perma.cc/2HLLKCBN]; Brown also refers to cows as “technology.” Philippa Nuttall, Pat Brown: “Farm Animals Are
the Most Destructive Technology on Earth,” NEW STATESMAN (Nov. 17, 2021),
https://www.newstatesman.com/the-environment-interview/2021/11/pat-brown-farm-animals-arethe-most-destructive-technology-on-earth [https://perma.cc/EH63-ASSV].
13. Throughout their lives, cows and animals used in agriculture are subjected to practices that
cause suffering. See, for example, research on common practices performed on cows in farms, such as
dehorning. Kevin J. Stafford & David J. Mellor, Addressing the Pain Associated with Disbudding and
Dehorning in Cattle, 135 APPLIED ANIMAL BEHAV. SCI. 226, 229 (2011)
https://www.sciencedirect.com/science/article/abs/pii/S0168159111003236?via%3Dihub
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Although both burgers are intended as hamburger replacements, they are
not alike in all aspects. The Impossible Burger is based on soy protein, while
the Beyond Burger is based primarily on pea protein.14 This turns out to be
significant because of the greater potential for allergic reactions from soy
products than from pea products.15 Another difference is that the Impossible
Burger contains genetically modified material for flavor, aroma, and color
enhancement.16 Soy leghemoglobin (heme) can be derived from root nodules
but not in amounts necessary to scale production of the Impossible Burger.17
[https://perma.cc/S2L2-QPP3]; Matthew L. Stock, Sarah L. Baldridge, Dee Griffin, & Johann F.
Coetzee, Bovine Dehorning: Assessing Pain and Providing Analgesic Management, 29 VETERINARY
CLINICS OF N. AM.: FOOD ANIMAL PRAC. 103 (2012) https://pubmed.ncbi.nlm.nih.gov/23438402/
[https://perma.cc/W7PX-FJWY]; Heather W. Neave, Rolnei R. Daros, João H. Costa, Marina A.G.
von Keyserlingk & Daniel M. Weary, Pain and Pessimism: Dairy Calves Exhibit Negative Judgement
Bias Following Hot-Iron Disbudding, 8 PLOS ONE, Dec. 2013, at 1, 4
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0080556 [https://perma.cc//K6EKS86V]; Daniela M. Meléndez, Sonia Marti, Derek B. Haley & Timothy D. Schwinghamer, Effects of
Conditioning, Source, and Rest on Indicators of Stress in Beef Cattle Transported by Road, 16 PLOS
ONE, Jan. 2021, at 1, 4 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244854
[https://perma.cc/6RAP-2H8H]. In 2019, the global organization World Animal Protection stated that
“between Impossible and Beyond estimated sales at national QSRs, around 140,000 pigs and 110,000
cows—or a quarter million total—will exit the food system every year.” Ben Williamson, Fast Food’s
Love of Plant-Based Meat Saves a Quarter Million Animals Per Year, WORLD ANIMAL PROT.: BLOGS
(Dec. 11, 2019), http://www.worldanimalprotection.us/blogs/fast-foods-love-plant-based-meat-savesquarter-million-animals-year [https://perma.cc/49JC-ABYQ].
14. See Impossible Burger, IMPOSSIBLE FOODS, https://impossiblefoods.com/products/burger
[https://perma.cc/7GZ7-WY9E]; Beyond Burger, BEYOND MEAT, www.beyondmeat.com/enUS/products/the-beyond-burger [https://perma.cc/LUZ3-NY6L]. Ethan Brown has stated that Beyond
also uses proteins from rice and mung bean in its burgers because “[o]ne goal of this innovation is to
diversify protein sources.” Larissa Zimberoff, The Rise of the Pea: How an Unassuming Legume
Emerged as a Frontrunner in the Race to Replace Meat and Dairy, TIME (August 15, 2019)
https://time.com/5652178/pea-meat-dairy-alternative/ [https://perma.cc/7VQJ-TYBK] (quoting Ethan
Brown).
15. Food
Allergies,
U.S.
FOOD
&
DRUG
ADMIN.
(Jan.
31,
2022),
https://www.fda.gov/food/food-labeling-nutrition/food-allergies
[https://perma.cc/6FPR-8QST]
(listing soybeans as one of the eight foods identified as “major food allergens” in the Food Allergen
Labeling and Consumer Protection Act of 2004); see also Steve L. Taylor, Justin T. Marsh, Stef J.
Koppelman, Jamie L. Kabourek & Philip E. Johnson, A Perspective on Pea Allergy and Pea Allergens,
116 TRENDS IN FOOD SCI. & TECH. 186, 186 (2021) (discussing pea allergies, but suggesting that peas
are
not
likely
to
be
as
allergenic
as
soy)
https://www.sciencedirect.com/science/article/abs/pii/S0924224421004556?via%3Dihub
[https://perma.cc/K45K-T6Q7].
16. Amanda Capritto, Impossible Burger 2.0: How Does It Taste, Is It Safe and Where Can You
Get It?, CNET (Nov. 8, 2019), https://www.cnet.com/health/nutrition/impossible-burger-everythingyou-need-to-know/ [https://perma.cc/U5MC-EU4P].
17. Big Brains Podcast, A Scientist’s Beef with the Meat Industry, with Impossible Foods’ Pat
Brown, UCHICAGO NEWS (July 1, 2021), https://news.uchicago.edu/big-brains-podcast-impossible-
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Accordingly, Impossible engineered yeast cells to produce its genetically
engineered heme (GE heme).18 Beyond uses beet root as a coloring agent that
produces “bleeding” characteristic of beef burgers, but Beyond incorporates
beet root without use of a genetically modified organism (GMO) such as
yeast.19 While Beyond relies on beet root for color primarily, Impossible claims
that its GE heme is important for meat-like flavor more than color
enhancement.20
This second distinction leads to a third distinction between the two
companies’ products: Impossible tested its GE heme on animals, even though
it’s not required under FDA rules, while Beyond reports that it did not conduct
animal testing.21 Several organizations that purport to care about the protection
of animals supported Impossible, despite the fact that it engaged in lethal animal

foods-ceo-pat-brown-meat-industry-plant-based-vegetarian [https://perma.cc/CS6N-GQYG] (“It took
us maybe the better part of a year, spending time out in Midwest soybean fields, digging off root
nodules, and using an inverted street sweeper to strip them off the roots. But eventually [we] decided
that for a whole variety of reasons, this was not going to be a scalable solution. And at that point we
decided, okay, we’re going to express the heme protein in yeast, by engineering the yeast cells to
produce the heme protein. The yeast cells, by the way, are completely able of making the heme
molecule itself. Every cell has to be able to make heme pretty much, or else they have to able to
scavenge it on every cell on Earth, including yeast. But you need a specific kind of protein to hold that
heme molecule, so that it protects it from oxidation. And then, when you cook, it unfolds and releases
it, and sets off this explosion of chemistry. So, we engineered yeast to express heme protein, and now
we have yeast cells that are world-class professional producers of heme protein.”) (quoting Pat Brown).
18. Id.
19. See Frequently Asked Questions, BEYOND MEAT, https://www.beyondmeat.com/en-US/faqs
[https://perma.cc/4CSK-VH3P] (“We start with simple plant-based, non-GMO ingredients.”) Beyond
the Headlines: A Clarification Regarding Beyond Meat and Impossible Foods, BEYOND MEAT (Aug.
15, 2017), https://www.beyondmeat.com/en-US/whats-new/beyond-the-headlines-a-clarificationregarding-beyond-meat-and-impossiblefoods [https://perma.cc/GY8B-MZ65] (“Beyond Meat does
not use GMO ingredients. We believe it is entirely possible to recreate meat directly from plants
without GMOs, and we would offer The Beyond Burger as evidence that we’re onto something.”);
Capritto, supra note 16.
20. Capritto, supra note 16; Lydia Mulvany & Deena Shanker, “Blood” Keeps Fake Meat Off
Retail Shelves, L.A. TIMES (Dec. 27, 2018), https://www.pressreader.com/usa/los-angelestimes/20181227/281921659164714 [https://perma.cc/9D5E-H2YY].
21. Yes, the Impossible Burger Is Vegan, BETTER EATING INT’L. (May 15, 2019),
https://bettereating.org/updates/yes-the-impossible-burger-is-vegan/ [https://perma.cc/B7TX-SXH4]
(“Some have argued that products made by companies like Impossible Foods . . . should not be
consumed by vegans because the companies tested on animals.”); Beyond the Headlines: A
Clarification Regarding Beyond Meat and Impossible Foods, supra note 19 (“Beyond Meat has never
tested our products or ingredients on animals. Our scientists are focused on identifying existing plantbased ingredients that emulate the properties of meat. For example, to achieve the beefy red color of
our Beyond Burger, they tested hundreds of vegetables and fruit extracts, before settling on a
combination of beet powder and annatto.”).
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tests.22 This Article thoroughly discusses the lack of necessity to engage in such
testing for any legal or marketing reasons and argues that such organizations
should consider that when advocating for particular companies or products.
Since development of bioengineered plant-based foods can be expected to
continue, investors that consider themselves animal-protective should require
developers to use non-animal tests to comply with FDA requirements.
What of consumers? Do they care about these differences of protein source,
inclusion of GMOs, and animal testing? As of 2019, it was reported that more
than fifty percent of consumers had never heard of pea protein.23 Soy is a
relatively cheaper ingredient, which consumers may like, but pea protein may
be preferable to consumers as they become increasingly aware of its particular
advantages, such as the lower allergenicity of pea protein, the prevalence of
non-GMO crops, and potentially greater sustainability of pea farming as
compared to soybean farming.24 It is well-established that consumers are wary
of GMOs in food.25 At the least, the use of GMOs would not increase consumer
22. The Good Food Institute’s CEO, Bruce Friedrich has spoken out in support of Impossible
Foods on a number of occasions, including a specific blog “Impossible Foods? No Question!” from
2018, where he states: “Humane foods took another step forward this week when the Food and Drug
Administration issued a ‘no questions’ letter to Impossible Foods regarding the safety of the Impossible
Burger’s soy leghemoglobin (heme) . . . .” Bruce Friedrich, Impossible Foods? No Question!, GOOD
FOOD
INST.
(July
24,
2018),
https://gfi.org/blog/impossible-foods-no-question/
[https://perma.cc/54LV-LB8K]; see also Yes, the Impossible Burger Is Vegan, supra note 21 (praising
Impossible Foods for creating a beef substitute that makes “veganism more normalized, convenient,
and accessible to millions of people, including and especially those living in rural areas,” arguing that
animal testing should not change the “vegan” characterization of Impossible Burger, and stating
erroneously that “[w]hile FDA policy doesn’t specifically require animal testing, historical precedent
is that the FDA will only grant approval if the applicant performs a feeding or digestibility study on
rats or mice”). Open Philanthropy invested in Impossible Foods in order to advance the development
of plant-based foods and based on the beliefs that the founder, Patrick Brown, is an outstanding
scientist, that bioengineered products may be more transformative than other plant-based alternatives,
and that the Impossible Burger’s taste would be appealing. Impossible Foods – R&D Investment, OPEN
PHILANTHROPY (Mar. 2017), https://www.openphilanthropy.org/grants/impossible-foods-rdinvestment/ [https://perma.cc/S9KB-5MSY].
23. Cathy Siegner, More Than 50% of Consumers Have Never Heard of Pea Protein, Survey
Finds, FOOD DIVE (Oct. 17, 2019), https://www.fooddive.com/news/more-than-50-of-consumershave-never-heard-of-pea-protein-survey-finds/564143/ [https://perma.cc/RUS8-D3BB].
24. Fatou Ndiaye, Tri Vuong, Jairo Duarte, Rotimi E. Aluko & Chantal Matar., Anti-Oxidant,
Anti-Inflammatory and Immunomodulating Properties of an Enzymatic Protein Hydrolysate from
Yellow
Field
Pea
Seeds,
51
EUR
J.
NUTRITION
29,
33–36
(2012)
https://pubmed.ncbi.nlm.nih.gov/21442413/ [https://perma.cc/C8DB-2SEQ]; Zimberoff, supra note
14.
25. Cary Funk, About Half of U.S. Adults Are Wary of Health Effects of Genetically Modified
Foods, but Many Also See Advantages, PEW RSCH. CTR. (Mar. 18, 2020), www.pewresearch.org/facttank/2020/03/18/about-half-of-u-s-adults-are-wary-of-health-effects-of-genetically-modified-foods-
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receptivity to a product when an equivalent product does not contain GMO
ingredients.
What about the third difference: animal testing of food ingredients? Some
research suggests that people care about animal welfare26 and that many prefer
personal care items not tested on animals.27 However, it has been unclear if
consumers would treat food products differently from personal care products.
Nevertheless, several major food companies, including Kellogg’s, General
Mills, and Coca-Cola, have made a point of letting consumers know that they
would not test on animals unless explicitly required by governmental
agencies,28 presumably because they believe it would be a negative for
consumers if they did. As will be discussed in Part I, FDA guidelines do not
require animal testing of food ingredients. Accordingly, these companies’
assurances can be understood as a commitment to avoid animal testing when
conducting food ingredient safety assessments for which formal FDA approval
is not required and to work with the FDA to use non-animal tests when formal
FDA review is required.29
So, how is it that a new, remarkably innovative company like Impossible
would test a new food ingredient, GE heme, on animals, when there are
established food companies that have committed to not testing on animals?
According to Impossible, “some large chains and several foreign countries

but-many-also-see-advantages/ [https://perma.cc/7H88-A7F9]; Sydney E. Scott, Yoel Inbar,
Christopher D. Wirz, Dominique Brossard & Paul Rozin, An Overview of Attitudes Toward
Genetically
Engineered
Food, 38
ANN. REV. NUTRITION 459, 459
(2018),
https://www.annualreviews.org/doi/abs/10.1146/annurev-nutr-071715051223
[https://perma.cc/7BPL-4378] (“Laypeople tend to see genetically engineered food as dangerous and
offering few benefits.”).
26. Amber Itle & Susan Kerr, Animal Welfare: A Complex Concept, 5 WHATCOM AG MONTHLY,
no. 6, 2016, at 1, 2 https://extension.wsu.edu/wam/animal-welfare-a-complex-concept/
[https://perma.cc/2WBP-89AX].
27. Kerry Postlewhite, Brands Can No Longer Ignore the 8.3 Million People Who Want End to
Animal
Testing,
REUTERS
EVENTS
(Oct.
14,
2018),
https://www.reutersevents.com/sustainability/brands-can-no-longer-ignore-83-million-people-whowant-end-animal-testing%20%5b [https:/perma.cc/G5C4-NUV9].
28. Kellogg
Company
Animal
Welfare
Commitment,
KELLOGG,
https://crreport.kelloggcompany.com/ppm-animal-welfare-commitment
[https://perma.cc/J57JZRPD]; Animal Welfare Policy, GEN. MILLS, https://www.generalmills.com/how-we-makeit/healthier-planet/sustainable-and-responsible-sourcing/animal-welfare
[https://perma.cc/E9S3M3CY]; Animal Health and Welfare Guiding Principles, COCA-COLA CO. (June 30, 2020),
https://www.coca-colacompany.com/policies-and-practices/animal-health-and-welfare-guidingprinciples [https://perma.cc/HL7J-ELR3].
29. See infra Part I (describing FDA safety assessment requirements that do not require formal
FDA approval and those that do).
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would sell our product only when we received a ‘no questions’ letter30 from the
FDA, which required a rat-feeding study.”31 Since thousands of substances in
the food supply have not been assessed for safety,32 it seems unlikely that
grocery stores would require such a letter. The major food companies listed
above and several others no longer conduct animal testing,33 yet their products
are readily available in grocery stores. It also seems unlikely that foreign
countries would rely on the United States FDA for safety assessments. For
instance, China and Europe have not yet opened their markets to Impossible’s
GMO-containing products, despite the fact that the FDA does not regulate use
of GMO ingredients other than requiring labeling.34
Even if particular grocery chains or foreign countries were to require an
FDA “no questions” letter, the central problem with Impossible’s argument is
that it conflates receipt of a “no questions” letter from the FDA with a
30. A “no questions” letter means that the FDA has reviewed the safety assessment methodology
and results and believes that the producer’s assessment meets FDA safety assessment requirements.
See infra Part I.
31. See PETA: The Unofficial Correction, IMPOSSIBLE FOODS (July 30, 2018),
https://assets.ctfassets.net/hhv516v5f7sj/q95roYbzJAMea22kkiwQ2/7256a4ab2c24d0ea4a903991ba
7150b1/PETA_The_Unofficial_Correction_FINAL.pdf [https://perma.cc/Y9NF-S67T]; See also
Mulvany & Shanker, supra note 20 (stating that the FDA treated Impossible’s GE heme as a color
additive, leading to more stringent tests, but not reporting that animal tests are necessary).
32. See, e.g., Maricel V. Maffini, Thomas G. Neltner & Sarah Vogel, We Are What We Eat:
Regulatory Gaps in the United States That Put Our Health at Risk, 15 PLOS BIOLOGY, Dec. 2017, at
1,
5
https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.2003578
[https://perma/cc/W49J-N3RU] (“Certainly, when it comes to managing the safety of chemicals in
food, the FDA has been sluggish to modernize its science and is falling far short in effectively
accounting for the safe use of thousands of chemicals in use today.”).
33. See Victory! Global Food Industries Ditches Deadly Animal Tests—See the List, PETA,
https://www.peta.org/features/victories-food-drink-companies-refuse-animal-tests/
[https://perma.cc/PV6D-CYJJ].
34. As of April 21, 2021, Impossible still lacked access to China and European countries because
they ban GMO foods and food ingredients. Siddharth Cavale & Uday Sampath Kumar, Analysis: Not
Impossible, Just Unlikely: Wall Street’s Plant-Based Love Wilts, REUTERS (Apr. 21, 2021),
https://www.reuters.com/business/faux-meat-growth-doubts-give-market-food-thought-impossible2021-04-21/ [https://perma.cc/E8QN-XZDN] (“Impossible’s burgers and sausages are available at
only 20,000 stores globally, versus Beyond’s 122,000 and it is still seeking regulatory approval in
Europe and mainland China, where the genetically modified yeast it uses is banned.”). With regard to
FDA’s lack of GMO regulations, see New Plant Variety Regulatory Information, U.S. FOOD & DRUG
ADMIN. (Mar. 30, 2020) https://www.fda.gov/food/food-new-plant-varieties/new-plant-varietyregulatory-information [https://perma.cc/W6CE-M3PL] (“The FDA regulates human and animal food
from plants, including plants produced through use of genetic engineering and genome editing, under
the Federal, [sic] Food, Drug, and Cosmetic Act (FD&C Act) and holds them to the same standards as
all foods produced, processed, stored, shipped or sold in the United States.”); Katharine Van Tassel,
Genetically Modified Plants Used for Food, Risk Assessment and Uncertainty Principles: Does the
Transition From Ignorance to Indeterminacy Trigger the Need for Post-Market Surveillance?, 15 B.U.
J. SCI. & TECH. L. 220, 239 (2009).
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requirement of animal testing. In fact, as will be shown in more detail in Part I,
the FDA does not require animal testing of food ingredients—not even color
additives, which require formal review.35 Indeed, requiring animal testing at
this point, when the science of product safety assessment has developed more
reliable safety assessment tools, would negatively impact consumer safety and
come at the cost of inflicting terrible and unnecessary animal suffering and
death. Use of alternative, more reliable safety assessment tools is important for
both human and animal welfare, and the FDA does not prevent a company from
using those tools.
From a food marketing point of view, it makes little sense to test on animals,
especially when other companies are making clear to consumers that they no
longer test on animals. This is true unless the manufacturer is targeting meateaters, believes that those consumers do not care about animal testing, and
safety assessments based on animals are the fastest and cheapest way to get
FDA approval. As will be explored in Part III, such a belief about meat-eating
consumers—or any consumers—would be misguided. Research conducted by
the author and Professor Adam Feltz in late January 2022 reveals that
consumers, including meat-eating consumers, clearly reject animal testing of
food ingredients.36
The idea that animal testing does not reliably predict risk to humans and
comes at too high a price for humans as well as animals is gaining traction. In
September 2022, the U.S. Senate passed by unanimous consent the FDA
Modernization Act 2.0 to end FDA’s mandate to test experimental drugs on
animals before clinical trials in humans.37 In October 2021, when a similar bill
was introduced in the Senate,38 the justification was both the lack of reliability
of animal testing and regard for animals used in those tests. According to one
of the co-sponsors of both bills, Senator Cory Booker (D-New Jersey), “Thanks
to modern scientific innovation, the use of animal toxicity testing for
experimental drugs has become increasingly obsolete . . . . This legislation will
eliminate unnecessary suffering for countless animals when scientifically

35. 21 C.F.R. § 70.10 (2021). For petition requirements for color additives, see 21 C.F.R. § 71.1
(2021). Soy leghemoglobin is considered a color additive. Peter Cassell, FDA In Brief: FDA Approval
of Soy Leghemoglobin As a Color Additive Is Now Effective, U.S. FOOD & DRUG ADMIN. (Dec. 17,
2019), https://www.fda.gov/news-events/fda-brief/fda-brief-fda-approval-soy-leghemoglobin-coloradditive-now-effective [https://perma.cc/HFJ8-38ZV].
36. This research included three pre-tests to refine the design and to determine the correct sample
size for the survey. See infra Part III.B.
37. FDA Modernization Act 2.0, S. 5002, 117th Cong. (2022).
38. FDA Modernization Act of 2021, S. 2952, 117th Cong. (2021). Another similar bill,
sponsored by Rep. Vern Buchanan (R-Florida), was introduced in the House of Representatives in
April 2021. FDA Modernization Act of 2021, H.R. 2565, 117th Cong. (2021).
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reliable alternative testing methods are available.”39 Similarly, the sponsor of
both bills, Senator Rand Paul (R-Kentucky), said that “[t]he FDA
Modernization Act would accelerate innovation and get safer, more effective
drugs to market more quickly by cutting red tape that is not supported by current
science. It would also prevent the needless suffering and death of animal test
subjects—which is something I think both Republican[s] and Democrats can
agree needs to end.”40
All things considered, it seems this would be a bad time for new and
otherwise innovative food companies to use outdated animal testing for food
ingredient safety assessments. This is particularly true since the FDA already
has a “Predictive Toxicology Roadmap” for the development and evaluation of
emerging toxicological methods for use in FDA regulatory review.41
This Article begins in Part I with the history and content of FDA rules
regulating pre-market safety assessments of novel food ingredients. It is clear
from the FDA’s own guidelines as published in its “Redbook 2000” (Redbook)
that the testing protocols it provides as examples are not required tests. That
these are but guidelines was confirmed by the Ninth Circuit in May of 2021 in
the case of Center for Food Safety v. U.S. FDA, in which the plaintiff claimed
that the FDA’s approval of Impossible’s GE heme was insufficient.42 Part II
considers whether there is any reason a reasonably risk-averse food producer
should test new ingredients on animals to reduce liability exposure from
consumer lawsuits alleging injury from a food ingredient. Included in Part II is
consideration of how courts evaluate the reliability and applicability of animal
test-based safety assessments. Because food product litigation concerning
additives is sparse, this section considers judicial evaluation of such evidence
in the analogous context of pharmaceutical product litigation. Judges are
skeptical that animal test data can reliably predict human safety risk because of
39. Press Release, Office of Senator Cory Booker, Booker, Paul Introduce Bipartisan FDA
Modernization
Act
To
End
Animal
Testing
Mandates
(Oct.
7,
2021),
https://www.booker.senate.gov/news/press/booker-paul-introduce-bipartisan-fda-modernization-actto-end-animal-testing-mandates [https://perma.cc/6P9A-A3QE].
40. Id. See also the press release issued by co-sponsor, John Kennedy (R-Louisiana), stating:
“Testing new drugs on animals is often risky for both animals and people. The FDA Modernization
Act would allow drug producers to improve safety by using more modern, humane and effective
testing.” Press Release, Office of Senator Kennedy, Kennedy, Paul Introduce Bill To Improve Drug
Safety
and
Reduce
Animal
Testing
(Oct.
7,
2021),
https://www.kennedy.senate.gov/public/2021/10/kennedy-paul-introduce-bill-to-improve-drugsafety-and-reduce-animal-testing [https://perma.cc/R3ZJ-Z2ZU].
41. FDA’s Predictive Toxicology Roadmap, U.S. FOOD & DRUG ADMIN. (Sept. 25, 2020),
https://www.fda.gov/science-research/about-science-research-fda/fdas-predictive-toxicologyroadmap [https://perma.cc/M9WT-UFWX].
42. Ctr. for Food Safety v. U.S. Food & Drug Admin., 854 F. App’x. 865 (9th Cir. 2021).
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the difficulty of extrapolation from animal test subjects to humans, particularly
when animals are subjected to massive doses to which humans would not be
exposed. Part III reports the perspective of consumers, beginning with a brief
consideration of the history of development of plant-based meat substitutes in
the United States. Part III also describes results from the survey conducted by
the author and Professor Adam Feltz in late January 2022, which was designed
to reveal attitudes toward animal testing to assess safety and toxicity of food
ingredients, beliefs about whether FDA rules do or should require animal
testing, and perspectives about product labeling when manufacturers or
ingredient suppliers have tested ingredients on animals.
The analysis presented in each of these Parts leads consistently in the
direction of avoiding animal testing as unnecessary, inadequately protective of
public safety, and as oppositional to consumer preferences for both food safety
and protection of animal welfare. The Conclusion discusses a few implications
of the information and perspectives provided in Parts I through III. These
include the need for consumer safety organizations, investors, and animal
protection organizations to seek the reduction of animal testing as a matter of
improved consumer safety and reduced infliction of suffering on animals; the
desirability of product safety assessment companies increasing capacity to
conduct non-animal safety assessment tests; the need for the FDA to update its
guidelines for product safety assessments; the wisdom and feasibility of the
FDA requiring companies that want to use animal tests instead of non-animal
tests to seek prior FDA approval in all cases; and provision of information to
consumers about products whose ingredients have been tested on animals so
that they can defend with their consumption dollars values of consumer safety
and respect for the welfare of animals.
PART I. FOOD AND DRUG ADMINISTRATION RULES REGARDING NOVEL FOOD
INGREDIENT TOXICITY TESTING
This Part examines the nature of food additive safety assessment required
under federal law and whether animal testing is necessary. This is an important
pair of questions. Animal testing has longevity as a chemical safety assessment
method, but longevity does not necessarily confer reliability, especially as
scientists continually develop new testing methods based on technological
developments and new understandings of what to measure. There is everincreasing evidence that animal methods of testing are not reliable for
predicting toxicity in humans.43 There is also increasing evidence that non43. See,
e.g.,
Donald
Ingber,
Human
Organs-on-Chips,
WYSS
INST.,
https://wyss.harvard.edu/technology/human-organs-on-chips [https://perma.cc/KR8T-2C68]; Aysha
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animal methods can be effective predicters of toxicity in humans, and there are
several methods available now.44 In light of significant and numerous
developments in alternative testing methodology, consumer safety advocates
should be supporting not just more safety assessments of substances with which
consumers have contact; they should be supporting use of the most reliable
assessment techniques available. If despite this evidence, the law requires

Akhtar, The Flaws and Human Harms of Animal Experimentation, 24 CAMBRIDGE Q. OF
HEALTHCARE ETHICS 407 (2015); Gail A. van Norman, Limitations of Animal Studies for Predicting
Toxicity in Clinical Trials: Is It Time To Rethink Our Current Approach?, 4 JACC: BASIC TO
TRANSLATIONAL SCI. 845 (2019); Kathy Archibald, Robert Coleman & Tamara Drake, Replacing
Animal Tests To Improve Safety for Humans, in ANIMAL EXPERIMENTATION: WORKING TOWARDS A
PARADIGM CHANGE 417 (Kathrin Herrmann & Kimberley Jayne eds., 2019). Systematic reviews that
have been conducted generally reveal the unreliability and poor predictability of animal tests. See Pablo
Perel, Ian Roberts, Emily Sena, Philipa Wheble, Catherine Briscoe, Peter Sandercock, Malcolm
Macleod, Luciano E. Mignini, Pradeep Jayaram & Khalid S. Khan, Comparison of Treatment Effects
Between Animal Experiments and Clinical Trials: Systematic Review, 334 BMJ, Jan. 2007
https://www.bmj.com/content/334/7586/197 [https://perma.cc/5J4H-2WZY]; Fiona Godlee, How
Predictive
and
Productive
Is
Animal
Research?,
348
BMJ,
Jun.
2014
https://www.bmj.com/content/348/bmj.g3719 [https://perma.cc/8F3F-9L7Y] ; Michael Benatar, Lost
in Translation: Treatment Trials in the SOD1 Mouse and in Human ALS, 26 NEUROBIOLOGY OF
DISEASE 1 (2006); Aysha Z. Akhtar, John J. Pippin & Chad B. Sandusky, Animal Studies in Spinal
Cord Injury: A Systematic Review of Methylprednisolone, 37 ALTERNATIVES TO LABORATORY
ANIMALS 43 (2009); Pandora Pound & Michael B. Bracken, Is Animal Research Sufficiently Evidence
Based To Be a Cornerstone of Biomedical Research?, 348 BMJ, May 2014
https://www.bmj.com/content/348/bmj.g3387 [https://perma.cc/8TP4-RVD8].
44. Ingber, supra note 43. Johns Hopkins University’s Center for Alternatives to Animal Testing,
https://caat.jhsph.edu/ [https://perma.cc/U6E4-C8PM], contains an extensive list of alternatives as well
as resources for more information and assistance with them. Researchers are involved with
governmental agencies to reduce or eliminate animal testing. See, e.g., Holly Ober, Finding
Alternatives
to
Animal
Testing,
UNIV.
CAL.
(Sept.
26,
2019),
https://www.universityofcalifornia.edu/news/finding-alternatives-animal-testing
[https://perma.cc/JF6C-352A]. PETA maintains a lengthy list of viable alternatives to animal testing.
Alternative Methods Validated for Regulatory Use, PETA, https://www.thepsci.eu/alternatives/
[https://perma.cc/MBA7-Q6MM]. The Animal-Free Safety Assessment Collaboration (AFSA)
provides information regarding the use of animals in safety assessment, the drawbacks of such testing,
and
non-animal
testing
alternatives.
Why
Animal-Free,
AFSA,
https://www.afsacollaboration.org/why-animal-free-faq/#alternatives_to_animal_testing
[https://perma.cc/B4W9-Q9WJ]. There is also scholarship on the subject. See, e.g., Rob B. M. de Vries,
Marlies Leenaars, Joppe Tra, Robbertjan Huijbregtse, Erik Bongers, John A. Jansen, Bert Gordjin &
Merel Ritskes-Hoitinga, The Potential of Tissue Engineering for Developing Alternatives to Animal
Experiments: A Systematic Review, 9 J. TISSUE ENG’G & REGENERATIVE MED. 771 (2015); Jagdish
Rai & Kuldeep Kaushik, Reduction of Animal Sacrifice in Biomedical Science & Research Through
Alternative Design of Animal Experiments, 26 SAUDI PHARM. J. 896 (2018); Agnes L. Karmaus, Hedi
Bialk, Suzanne Fitzpatrick & Mansi Krishan, State of the Science on Alternatives to Animal Testing
and Integration of Testing Strategies for Food Safety Assessments: Workshop Proceedings, 110
REGUL. TOXICOLOGY & PHARMACOLOGY, Nov. 2019 https://www.sciencedirect.com/science/
article/pii/S027323001930279X?via%3Dihub [https://perma.cc/V39D-Zh2Z].
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animal testing to assess safety of food additives, then food safety will be
compromised, and animals will be needlessly subjected to tremendous
suffering.45
PETA is one of a few organizations that maintain lists of numerous tests,
along with information about their lower reliability than non-animal testing
methods.46 For purposes of this Article, however, perhaps consideration of one
test that is still commonly in use will suffice to convey the magnitude of
suffering inflicted on animals. The “lethal dose 50” (LD50) is a type of “acute
toxicity test,” described as follows by People for the Ethical Treatment of
Animals:
To determine the danger of a single short-term exposure to
a product or chemical, the substance is administered to animals
(usually rodents) in extremely high doses via force-feeding,
forced inhalation, and/or eye or skin contact. Animals in the
highest-dose groups often endure severe abdominal pain,
diarrhea, convulsions, seizures, paralysis, or bleeding from the
nose, mouth, or genitals before they ultimately die or are
killed . . . . In [the LD50] test, groups of animals are force-fed
increasing amounts of a test substance or increasing amounts
are applied to their skin until half of them die.47
Importantly, this test was not subjected to validation analysis until recently,
and, in fact, it is a quite poor predictor (65% accuracy) when compared to
human cell-line tests (75%–85% accuracy).48 It is also important to note that

45. There is little incentive for entities that test on animals to report their suffering. Such
reporting is left to animal protection nonprofits. See, e.g., Animal Testing Facts and Alternatives,
PETA,
https://www.peta.org/issues/animals-used-for-experimentation/animal-testing-101/
[https://perma.cc/B6GX-P9PX];
Taking Suffering Out of Science, HUMANE SOC’Y U.S.,
https://www.humanesociety.org/all-our-fights/taking-suffering-out-science [https://perma.cc/87N2FBJP]; Testing Chemicals on Animals, ROYAL SOC’Y FOR PREVENTION CRUELTY TO ANIMALS,
https://www.rspca.org.uk/adviceandwelfare/laboratory/testingchemicals
[https://perma.cc/3EL28UNG];
There are various tests. Animals Used for Experimentation Factsheets, PETA,
https://www.peta.org/issues/animals-used-for-experimentation/animals-used-experimentationfactsheets/ [https://perma.cc/J8LJ-QBRQ].
46. Toxic and Tragic Consequences of Product Testing on Animals, PETA,
https://www.peta.org/issues/animals-used-for-experimentation/animals-used-experimentationfactsheets/product-testing-toxic-tragic/ [https://perma.cc/873N-W4FX].
47. Id.
48. Id. (“One international study that examined the results of rat and mouse LD50 tests for 50
chemicals found that these tests predicted toxicity in humans with only 65 percent accuracy––while a
series of human cell-line tests was found to predict toxicity in humans with 75 to 80 percent accuracy.”)
(citing B. Ekwall, Overview of the Final MEIC Results: II. The In Vitro–In Vivo Evaluation, Including
the Selection of a Practical Battery of Cell Tests for Prediction of Acute Lethal Blood Concentrations
in Humans, 13 TOXICOLOGY IN VITRO 665 (1999)).
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there are less severe tests available, which Impossible used.49 That said, the
main driver of this section is the lack of necessity to inflict any suffering on
animals. Whatever one might think about how much suffering is acceptable to
inflict on animals, lack of necessity to do it at all makes any amount of suffering
ethically problematic. Thus, the question of legal necessity takes on particular
importance.
Considering the highly questionable safety benefits to humans and the
infliction of suffering of animals, it is important to know what FDA regulations
and the FDA require for assessing safety of food ingredients. To answer this
question, it is necessary to consider the history through which the law
developed in this area because it partially explains current FDA decisionmaking.
A. History and Structure of Food and Drug Administration Requirements
The law that governs this area was enacted in 1958 when the 1938 Food
Drug and Cosmetic Act (FDCA) was amended to require premarket approval
by the FDA for new food ingredients.50 Its stated purpose was to charge FDA
with preventing the use of unsafe food ingredients.51 At that time, FDA
estimated that only half of the chemicals currently used in food had been
affirmatively found to be safe.52 Current estimates are difficult to derive, but
there is little doubt that the number of ingredients subjected to explicit FDA
review is far less than the number of ingredients in commerce.53 As explained
49. Those tests included the following: Subacute Toxicity 14-Day test (48 animals) as a
precursor to a 28-Day Repeated Dose Toxicity test (80 animals), and a 28-Day Investigative Study in
Rats with 14-Day Estrous Cycle Pre-Screen (60 female animals and involving vaginal lavage). Rachel
Z. Fraser, Mithila Shitut, Puja Agrawal, Odete Mendes & Sue Klapholz, Safety Evaluation of Soy
Leghemoglobin Protein Preparation Derived From Pichia pastoris, Intended for Use as a Flavor
Catalyst in Plant-Based Meat, 37 INT’L J. TOXICOLOGY 241, 244–60 (2018). Experimental
observations included ophthalmologic evaluations, clinical observations, body weights, food
consumption, clinical pathology including blood chemistry, hematology, coagulation, and urinalysis,
gross necropsy, organ weights, and histopathology. Id.
50. Paul R. Hanlon, Joy Frestedt & Kelly Magurany, GRAS from the Ground Up: Review of the
Interim Pilot Program for GRAS Notification, 105 FOOD & CHEM. TOXICOLOGY 140, 140 (2017); see
also Carrie A. Scrufari, Substances Generally Recognized as Safe - Until They’re Not: Challenges in
Protecting the Food Supply in a Processed World, 36 STAN. ENVTL. L. J. 219, 226–30 (2017), for a
more in-depth history of the passage of the FFDCA and the 1958 amendment.
51. Scrufari, supra note 50, at 228.
52. Id.
53. Scrufari notes in her article, the “NRDC[Natural Resources Defense Council] estimates that
there are as many as 1,000 chemicals that manufacturers have designated as GRAS [Generally
Recognized As Safe], but whose safety FDA has not reviewed or approved.” Id. at 238 (citing Tom
Neltner & Maricel Maffini, Generally Recognized as Secret: Chemicals Added to Food in the United
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in more detail below, that is because of how time-consuming FDA premarket
review of each substance would be, the way the law is written such that FDA
has broad discretion in how it fulfills its duty, and how manufacturers comply
with the law.
Under 21 U.S.C.A. § 321(s), a “food additive” is “any substance the
intended use of which results or may reasonably be expected to result, directly
or indirectly, in its becoming a component or otherwise affecting the
characteristics of any food (including any substance intended for use in
producing . . . packing, processing).”54 That same subsection goes on to provide
that substances generally recognized as safe (GRAS) under the circumstances
of their intended uses, as determined by experts qualified to evaluate the safety
of substances, would not be considered a food additive at all.55 The FDA
Commissioner has the authority to evaluate the safety of a substance and to take
a number of different actions, such as determining it to be GRAS or regulating
or prohibiting the use of the substance as a food additive.56 However, FDA took
States, 4 (2014), https://www.nrdc.org/sites/default/files/safety-loophole-for-chemicals-in-foodreport.pdf [https://perma.cc/BF6S-2BS7]). The cited NRDC study goes on to say that:
All told, we were able to identify 275 chemicals from 56 companies that
appear to be marketed for use in food based on undisclosed GRAS safety
determinations. This is likely the tip of the iceberg—we previously published in
an industry journal an estimate that there have been 1,000 such secret GRAS
determinations.
Tom Neltner & Maricel Maffini, Generally Recognized as Secret: Chemicals Added to Food in the
United States, 4 (2014), https://www.nrdc.org/sites/default/files/safety-loophole-for-chemicals-infood-report.pdf [https://perma.cc/BF6S-2BS7] (citing Thomas G. Neltner, Neesha R. Kulkarni,
Heather M. Alger, Maricel V. Maffini, Erin D. Bongard, Neal D. Fortin & Erik D. Olson, Navigating
the U.S. Food Additive Regulatory Program, 10 COMPREHENSIVE REVS. FOOD SCI. & FOOD SAFETY
342, 342 (2011)). In fact, it is difficult to know how many untested chemical substances of all types
exist in consumer products, with estimates ranging widely. See, e.g., Debunking the Myths: Are
There Really 84,000 Chemicals?, CHEMICALSAFETYFACTS (Aug. 17, 2022),
https://www.chemicalsafetyfacts.org/health-and-safety/debunking-the-myths-are-there-really-84000chemicals/ [https://perma.cc/RN3P-6CG6].
54. 21 U.S.C. § 321(s). There are enumerated exceptions, including: “(2) a pesticide
chemical . . . (3) a color additive . . . [and] (6) an ingredient . . . intended for use in, a dietary
supplement.” These exceptions are treated differently. Pesticides require target animal efficacy tests.
Color additives require a higher standard of “convincing evidence,” 21 C.F.R. § 70.3(i) (2021), than
GRAS determinations, and FDA review is required, 21 C.F.R. § 70.10 (2021). However, just like with
GRAS approvals, animal testing is not required to satisfy the standard and FDA is willing to consider
non-animal testing protocols. See infra note 99 and accompanying text.
55. 21 U.S.C. § 321(s); See also 21 C.F.R. § 170.30(a) (2021) (“General recognition of safety
may be based only on the views of experts qualified by scientific training and experience to evaluate
the safety of substances directly or indirectly added to food.”).
56. “The Commissioner, on his own initiative or on the petition of any interested person, . . . may
issue a notice in the Federal Register proposing to determine that a substance is not GRAS and is a
food additive subject to section 409 of the [Federal Food, Drug, and Cosmetic] Act.” 21 C.F.R.
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the position that food industry companies could evaluate whether a novel food
ingredient is GRAS and provided an opportunity for a company to petition the
FDA to review its GRAS determination. “By 1961, FDA had amended its
regulations to include a list of food substances that are GRAS under certain
conditions of use (the GRAS list),”57 which is published in the Code of Federal
Regulations.58 During the 1960s, many manufacturers requested FDA’s
opinion, perhaps because of a desire for publication of a substance on the GRAS
list or for assurance that they had complied sufficiently to avoid subsequent
compliance investigations.59
According to FDA, Congress initially believed that most substances in use
at that time would not require formal review because of long enough use by the
public to have confidence in their safety or because of “the nature of the
substances, their conditions of use, and the information generally available to
scientists.”60 However, in 1969, due to continuing public concern about food
safety, then-President Nixon ordered FDA to review all the food ingredients it
had listed as GRAS.61 FDA created the Select Committee on GRAS Substances
(SCOGS), on which various scientists served to evaluate the scientific
information available for GRAS-listed substances.62
Progress was slow. It took a decade for SCOGS to develop opinions on the
safety of only 422 GRAS substances.63 Of those 422, SCOGS recommended
revocation of the GRAS status of thirty of them and identified five additional
substances it considered worrisome at what it deemed to be current levels of
consumption.64 After all of that work, FDA allowed the GRAS status for
seventeen of that group of thirty-five substances recommended for revocation

§ 170.38(b)(1). After evaluation, the Commissioner may decide that a substance is GRAS, id. at
§ 170.38(b)(3), but if the Commissioner decides that it is not GRAS, the Commissioner has the
authority to “promulgate a food additive regulation governing use of the additive,” either temporarily
or permanently, or “require discontinuation of the use of the additive” or “adopt any combination of
[those] three approaches for different uses or levels of use of the additive.” Id. at § 170.38(c)(1)–(4).
57. FDA’s Approach to the GRAS Provision: A History of Processes, U.S. FOOD & DRUG
ADMIN.,
https://www.fda.gov/food/generally-recognized-safe-gras/fdas-approach-gras-provisionhistory-processes [https://perma.cc/6CW8-U35K] (Jan. 4, 2018).
58. Id. The current list appears in 21 C.F.R. pts. 182, 184, 186.
59. FDA’s Approach to the GRAS Provision: A History of Processes, supra note 57.
60. Id.
61. Id.
62. Id.
63. GAO, FDA SHOULD STRENGTHEN ITS OVERSIGHT OF FOOD INGREDIENTS DETERMINED TO
BE GENERALLY RECOGNIZED AS SAFE (GRAS) 20 (2010), https://www.gao.gov/products/gao-10-246
[https://perma.cc/G9PZ-ENUQ].
64. Id. at 20–21.
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or considered worrisome; FDA neither approved nor revoked the GRAS status
of the other eighteen substances and provided no explanation for its silence.65
In 1972, while the SCOGS review was underway, FDA conducted
rulemaking to create procedures to review the GRAS determinations of various
substances.66 FDA also established the GRAS affirmation petition process
(GAP).67 GAP did not require companies to petition FDA to affirm their GRAS
determinations, but submitting a GAP petition may have been perceived as an
opportunity to have substances publicly GRAS-listed and as an appropriate
risk-limiting decision.68 Ultimately, the FDA, through SCOGS, abandoned
review of GRAS-listed substances, citing lack of funding.69
In 1974, FDA further clarified the distinction between GRAS substances
and food additives, saying that a substance could be GRAS through a
demonstration of a “general recognition of safety” by either scientific
procedures or by experience grounded in the common usage in food for
substances used in food before 1958.70 Then, in 1997, FDA published a
Proposed Rule outlining a voluntary GRAS notification process and interim
policy to replace the “resource-intensive” GRAS affirmation petition process.71
As part of an Interim Pilot Program, manufacturers could notify FDA of their
GRAS determinations.72 The safety assessment and basis for the GRAS
notification would be the responsibility of the manufacturer.73

65. Id. at 21.
66. U.S. FOOD & DRUG ADMIN., supra note 57.
67. Id.
68. Scrufari, supra note 50, at 233–34. Scrufari notes that “[h]istorically, however, FDA has
seldom brought enforcement actions against manufacturers regarding their use of GRAS substances.”
Id. at 234.
69. Id. at 235.
70. 21 C.F.R. § 170.30(a) (2021). The FDA regulations also clarify that:
General recognition of safety requires common knowledge throughout the
scientific community knowledgeable about the safety of substances directly or
indirectly added to food that there is reasonable certainty that the substance is not
harmful under the conditions of its intended use . . . . General recognition of
safety through scientific procedures shall be based upon the application of
generally available and accepted scientific data, information, or methods, which
ordinarily are published, as well as the application of scientific principles, and
may be corroborated by the application of unpublished scientific data,
information, or methods.
Id. § 170.30(a)–(b).
71. U.S. FOOD & DRUG ADMIN., supra note 57.
72. Id.
73. Id.

BRYANT_21NOV22 (DO NOT DELETE)

2022]

NOVEL FOOD INGREDIENTS

115

Notifying FDA did not have the legal effect of placing safety assessment
responsibility on the FDA. FDA could provide one of three possible responses:
1. No Questions: The FDA has no questions upon completing
their review regarding the GRAS status of the substance under
the intended conditions of use
2. Withdrawn: At the [manufacturer’s] request, the FDA has
ceased to evaluate the GRAS Notification
3. No Basis: The GRAS Notification does not provide a
sufficient basis to determine the substance is GRAS under the
intended conditions of use74
If the FDA responds with a “No Basis” letter or indicates in some way that
they will likely do so, the manufacturer has the option to address issues raised
by the FDA and resubmit its notification.75 On the other hand, the manufacturer
may withdraw its notification to the FDA and begin to sell food containing the
substance without any kind of FDA approval,76 as long as it has completed the
GRAS assessment.77 This provides something of a “best of both worlds” to
manufacturers, and it is not surprising that over 600 notifications were filed
during the Interim Pilot Program.78 The Proposed Rule made notification more
appealing, also, because it set a ninety-day review period and created a publicly
accessible website repository of GRAS notices, which provides the disposition
or outcome of each FDA review.79

74. Hanlon, Frestedt & Magurany, supra note 50, at 141. As of Oct. 27, 2022, 1,068 GRAS
Notifications appear on the FDA GRAS Notices website. GRAS Notices, U.S. FOOD & DRUG ADMIN.,
https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices
[https://perma.cc/7KSX-6ZMQ]. Of those, the FDA provided a “No Questions” response in 77% (822).
17% (183) were withdrawn at the notifier’s request, 2% (17) received a “No Basis” response, and 4%
(47) were still pending FDA resolution. Id. These numbers are helpful only in reflecting the percentage
of the different types of FDA responses, but they are not helpful in understanding the extent of use of
new substances. It is not possible to know how many times companies completed safety assessments
to meet GRAS requirements without submitting petitions for review. See Scrufari, supra note 50, at
238–40, 264–65.
75. Scrufari, supra note 50, at 235–36.
76. Id. at 237.
77. See 21 C.F.R. § 170.30(a) (2021).
78. Hanlon, Frestedt & Magurany, supra note 50, at 142.
79. Id. at 141–42 (citing U.S. FOOD & DRUG ADMIN., supra note 74). “This website provides
the substance name, GRAS Notification (GRN) number assigned by FDA, the FDA letter sent in
response to the notice, name and address of the notifier (the person making the GRAS determination),
substance conditions of use, and the basis of the determination (whether by scientific process or history
of use prior to 1958).” Hanlon, Frestedt & Magurany, supra note 50, at 141 (citing U.S. FOOD & DRUG
ADMIN., supra note 74).
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The Proposed Rule was finalized in 2016.80 With the final rule in place,
manufacturers may rely on a GRAS status only if they have taken steps to assess
the safety of a substance added to food, which requires scientific rigor.81 In a
piece of nonbinding guidance, FDA explained that “[f]or a substance to be
GRAS [through scientific procedures], the scientific data and information about
the use of a substance must be widely known and there must be a consensus
among qualified experts that those data and information establish that the
substance is safe under the conditions of its intended use.”82 GRAS designations
require the same scientific rigor as that “required to obtain approval” for a food
additive (that is, a substance not exempt as GRAS),83 but manufacturers need
not share the actual data on which their claim is based.84 Indeed, if a
manufacturer, in compliance with the GRAS rules, determines on its own that
the substance it proposes to use is safe, it can proceed to market without even
notifying the FDA of the existence of the substance, the process they undertook
to determine safety, or the specific outcomes of that process.85 This is why it is
very difficult to ascertain how many companies use animal tests.
Since the SCOGS review, the FDA has not initiated review of GRAS
substances. Instead, “FDA reviews the safety of GRAS food items only when
specific issues are raised regarding particular substances.”86 There is no
apparent attention to proactively developing lists of particularly reliable tests or
spot-checking compliance with GRAS safety assessment requirements. Animal
tests much less reliable than non-animal tests can be used without regard to their
potential costs to consumer safety or infliction of suffering on animals for no
or minimal benefit to humans.
Carrie Scrufari is among the critics of the GRAS process who have
articulated that far from the lax regulations working to decrease stress on the
industry and regulators alike, the program has created loopholes for

80. Hanlon, Frestedt & Magurany, supra note 50, at 141 (citing Substances Generally
Recognized as Safe, 81 Fed. Reg. 54960 (Aug. 17, 2016) (to be codified at 21 C.F.R. pts. 20, 25, 170,
184, 186, 570)).
81. See supra note 70 and accompanying text.
82. How U.S. FDA’s GRAS Notification Program Works, U.S. FOOD AND DRUG ADMIN.,
https://www.fda.gov/food/generally-recognized-safe-gras/how-us-fdas-gras-notification-programworks [https://perma.cc/5BVM-3NE8] (Feb. 9, 2018).
83. Scrufari, supra note 50, at 234 (quoting 21 C.F.R. § 170.30(b)).
84. See GAO, supra note 63, at 12, 20, 25.
85. See id. at 8, 12, 25, 36.
86. Scrufari, supra note 50, at 235.
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manufacturers that place a huge burden on regulators and the public.87 She
writes:
FDA hoped that, by minimizing the time required to review
GRAS substances and by easing the burden on industry to
submit information related to GRAS substances, industry
would be motivated to comply with the less onerous
requirements associated with the voluntary notification
procedure. However, in reality, the GRAS voluntary
notification scheme has incentivized industry to evade the
costly and timely additive pre-market regulatory approval
process by allowing food manufacturers to simply designate
new substances as GRAS without any government oversight.
Industry is not required to notify FDA of any new GRAS
designations, nor is industry required to prove the safety of any
of its proposed GRAS designations. In the event FDA
disagrees with a manufacturer’s proposed GRAS designation,
the manufacturer simply withdraws the GRAS notice, requests
that FDA cease its evaluation of the substance, and then
continues using the substance in the food supply. . . . [T]he
result has been the creation of a giant backdoor – a loophole of
epic proportions . . . . Currently, the average estimated time to
approve a food additive exceeds six years. The time and
expense . . . incentivizes industry to designate new food
substances as GRAS rather than as additives. . . . Moreover,
many manufacturers “base their GRAS determinations on
stale, conflict-ridden, and often unpublished, non-peerreviewed science.”88
With these frustrations and concerns in mind, in 2017, the Center for Food
Safety and others brought suit in the U.S. District Court for the Southern
District of New York, claiming that FDA’s interpretation of the law, allowing
manufacturers to make safety assessments of products they want to sell,
impermissibly “sub-delegates” to manufacturers FDA’s responsibility to ensure

87. Id. at 236–37; see also Neltner & Maffini, supra note 53, at 3 (stating the Natural Resources
Defense Council’s belief that a more accurate name for the “GRAS loophole” is “Generally
Recognized as SECRET”).
88. Scrufari, supra note 50, at 236–37 (quoting Comment from the Ctr. for Sci. in the Pub. Int.,
Consumers Union, Env’t Working Group & Nat. Res. Def. Council on Docket No. FDA-1997-N-0020
to
Commissioner
of
Food
and
Drug
Administration
at
16
(Apr.
2015)
https://www.cspinet.org/sites/default/files/attachment/GRAS%20Comment%20FINAL_0.pdf
[https://perma.cc/6MXM-E3U8]).
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the safety of food additives.89 On September 30, 2021, the New York district
court ruled in favor of FDA, finding that there was no impermissible subdelegation.90 However, an indication that the matter is not fully resolved is U.S.
Representative Rosa DeLauro’s introduction on June 4, 2021, of a bill that
would change the law in the direction preferred by Center for Food Safety: the
FDA would have to conduct a premarket review of the safety of ingredients,
rather than relying on manufacturers to bear sole responsibility for assessing
safety.91
While FDA abandoned its attempt to comprehensively assess GRAS-listed
substances in the 1970s because of cost,92 Congress’s ultimate decision might
turn on its view of how protected the public is under the current system, how
much increased safety can be derived from FDA-led premarket reviews, and
the level of funding to secure perhaps only small marginal gains in food safety.
Congress should consider that the public would derive more benefit from
requiring the most reliable predictive tests than from arguing about who
orchestrates the testing—the FDA or manufacturers. If predictive reliability
were the focus, the state of the science is such that much less animal testing
would occur, with significant increases in consumer safety. The next section
explores this idea that improved public safety can emerge from attention to the
types of tests conducted, including their relative costs, reliability in predicting
harm, and time needed to get those reliable data.
B. Is Animal Testing Required for GRAS Status?
No matter who conducts the safety assessment, basic questions exist about
how food ingredient safety evaluations should be conducted. Must evaluators
have training in a variety of safety evaluation techniques? Does the law require
specific kinds of tests? Should assessments include the use of nonhuman
species to test probable effects in humans?
To review, federal law requires that GRAS determinations be based on the
views of experts. In one of its guidance documents, the FDA states that for
89. Jessica L.A. Marks, Center for Food Safety Alleges FDA’s GRAS Rule is Unlawful,
FINNEGAN: BLOGS (May 22, 2017), https://www.finnegan.com/en/insights/blogs/ip-fda-blog/centerfor-food-safety-alleges-fdas-gras-rule-is-unlawful.html
[https://perma.cc/9KPV-GKF4].
This
litigation followed a similar suit brought in 2014 by the Center for Food Safety in the U.S. District
Court for the District of Columbia, which was settled later that year through a consent decree. Id.; see
also Scrufari, supra note 50, at 238.
90. Ctr. for Food Safety v. Becerra, 565 F. Supp. 3d 519, 543 (S.D.N.Y. 2021).
91. Toxic Free Food Act, H.R. 3699, 117th Cong. (2021). A similar bill was introduced in the
Senate by Senator Edward Markey on May 26, 2022. Ensuring Safe and Toxic-Free Foods Act, S.
4316, 117th Cong. (2022).
92. Scrufari, supra note 50, at 235.
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determinations based on scientific procedures, the relevant scientific data must
be “widely known,” and there must be a “consensus among qualified experts”
that the data “establish that the substance is safe under the conditions of its
intended use.”93
Hanlon notes that “[a]lthough not specifically required by the Final Rule, a
Notifier may convene a panel of appropriate experts who have expertise
demonstrated by training and experience (a GRAS Expert Panel) to review the
safety of the substance and to satisfy the requirement for this safety being
‘common knowledge throughout the scientific community.’ ”94 FDA defines a
GRAS panel as “a panel of qualified experts who are convened to evaluate
whether the available scientific data, information, and methods establish that a
substance is safe under the conditions of its intended use in human food or
animal food.”95 Further, the agency provides information about how to create a
panel so as to avoid conflicts of interest and bias.96
If a manufacturer chooses to file a GRAS notification instead of simply
fulfilling the requirement without notifying FDA, it must include information
about the scientific procedures used to assess safety, which include the
application of scientific data (including, as appropriate, data from “human,
animal, analytical, or other scientific studies”), information, and methods,
“whether published or unpublished,” as well as the application of scientific
principles, “appropriate to establish the safety of a substance” under the
conditions of its intended use.97 This list, which appears in the Code of Federal
Regulations, contains some non-animal testing methods. However, the
Redbook, the FDA’s handbook of guidance for GRAS assessment, describes
numerous animal study methods FDA says could satisfy testing requirements.98
Although many guidelines include animal testing protocols, the Redbook
states in its Introduction:
FDA’s guidance for toxicity studies for food ingredients
continue [sic] to emphasize that there is no substitute for sound
scientific
judgement.
This
guidance
presents

93. See supra notes 55, 70, 82 and accompanying text.
94. Hanlon, Frestedt & Magurany, supra note 50, at 141 (quoting 21 C.F.R. § 170.30(a)).
95. U.S. FOOD & DRUG ADMIN., BEST PRACTICES FOR CONVENING A GRAS PANEL: GUIDANCE
FOR
INDUSTRY
16
(Nov.
2017),
https://www.fda.gov/media/109006/download
[https://perma.cc/8MKW-5E6M].
96. Id. at 8.
97. 21 C.F.R. § 170.3(h) (2021).
98. See Redbook 2000: IV.B.1. General Guidelines for Designing and Conducting Toxicity
Studies, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/regulatory-information/search-fdaguidance-documents/redbook-2000-ivb1-general-guidelines-designing-and-conducting-toxicitystudies [https://perma.cc/3UW5-Tx2v] (Oct. 26, 2017).
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recommendations—not hard and fast rules. If an investigator
believes that he/she can provide the Agency with useful
toxicological information by modifying a recommended study
protocol, and is able to support the modification with sound
scientific arguments, then the investigator should propose the
modified protocol to the appropriate program division within
[the Office of Food Safety]. As always, petitioners and
notifiers should consult with the FDA prior to and during the
design of study protocols for toxicity studies and/or before
commencement of studies.
FDA’s guidance documents, including this guidance, do not
establish legally enforceable responsibilities. Instead,
guidances describe the Agency’s current thinking on a topic
and should be viewed only as recommendations, unless
specific regulatory or statutory requirements are cited. The use
of the word should in Agency guidances means that something
is suggested or recommended, but not required.99
Toxicologist Dr. Claire Kruger states that “it is critical to remember that
[the] Redbook does not provide this guidance as a checklist. The reason for the
flexibility in approach is that science evolves. Thinking evolves. Risk
assessments should incorporate and embrace these new advances.”100
That Redbook guidelines are non-binding was also emphasized by the
Ninth Circuit when deciding Center for Food Safety’s lawsuit against FDA for
allegedly improperly approving Impossible’s GE heme ingredient despite
Impossible’s failure to fully follow one of the safety assessment guidelines.101
In its May 3, 2021, decision, the Ninth Circuit emphasized that “CFS’s
contention that one study Impossible commissioned did not conform to the
FDA’s ‘Redbook’ is unavailing; the agency’s recommendations regarding the
design of toxicology studies are non-binding.” 102 Not only are the guidelines
non-binding, many reliable alternative non-animal safety assessment measures

99. Redbook 2000: I Introduction, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/redbook-2000-i-introduction [https://perma.cc/VXS8NPQY] (Jan. 30, 2018).
100. Claire Kruger, The Relevance of International Assessments to GRAS Determinations, 79
REGUL. TOXICOLOGY & PHARMACOLOGY S119, S121 (2016).
101. Ctr. for Food Safety v. U.S. Food & Drug Admin., 854 F. App’x. 865, 866 (9th Cir. 2021).
102. Id. Center for Food Safety argued that FDA should hold Impossible to a higher evidentiary
standard of safety than it did because color additives require FDA approval. Id. For purposes of this
Article, whether GE heme is a color additive is not an important issue because animal testing is not
required to meet either the GRAS standard or the color additives standard. The Redbook guidelines
apply to both, and the Ninth Circuit discussed the relevance of the Redbook as a source of guidelines
only. Id.
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are available.103 Consumers are not protected by more animal testing, they are
protected by better tests that more accurately predict negative human health
effects than animal-based tests.
A significant challenge for manufacturers seeking to avoid animal testing
stems from the fact that safety assessments must be tailored. Manufacturers
cannot select just any non-animal-based test; it is necessary to consult with
scientists because it is within the expertise of scientists to choose the most
appropriate test for the type of substance and circumstances of intended use.
This could turn out to be a complicated decision, turning on genuine desire for
accuracy in safety testing, the market advantage anticipated from being able to
claim that a product is free of animal testing, the cost of non-animal protocols
compared to animal protocols, perceptions of FDA’s willingness to promptly
consider proposed testing plans, and the availability of experts trained in nonanimal test methods.
Despite the fact that FDA rules allow for the use of non-animal tests,
manufacturers might be likely to use animal test protocols as a matter of habit
and misguided acceptance of FDA examples as requirements.104 Since the FDA
describes at least one sample animal-based test at each of the three “concern
levels” and provides limited examples of non-animal alternative tests,105 it
seems unlikely that food producers would go out of their way to search for nonanimal testing protocols, even though their use is allowed. A manufacturer that
contracts with product safety assessment companies, rather than doing in-house
assessment, would have to know to look for a company that has the willingness
and capacity to conduct non-animal-based assessments. Thus, an important
factor in the type of safety testing used is the extent of industry reliance on
scientists and product testing companies that use animal testing as standard
protocols for meeting their clients’ FDA safety assessment needs. Scientists and
companies set up to run testing in accordance with Redbook guidance can
satisfy most customers without incurring costs of ramping up to conduct nonanimal tests. If the number and type of testing services are limited,
manufacturers will have fewer choices, even if more appropriate non-animal
103. See supra note 44 and accompanying text.
104. The extent of non-animal and animal testing cannot be known exactly because
manufacturers do not have to supply that information unless seeking some kind of approval from FDA.
A full evaluation of the GRAS notices database would not fully reveal manufacturers’ decisions
because manufacturers satisfied with completion of GRAS requirements without notifying FDA would
not be listed.
105. Guidance for Industry: Summary Table of Recommended Toxicological Testing for
Additives Used in Food, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/guidance-industry-summary-table-recommendedtoxicological-testing-additives-used-food [https://perma.cc/H3NG-A4RK] (Sept. 20, 2018).

BRYANT_21NOV22 (DO NOT DELETE)

122

MARQUETTE LAW REVIEW

[106:97

test methods are available. A large shift in the direction of non-animal testing
could occur if product safety testing companies develop the capacity to perform
various non-animal testing protocols. This could, in turn, be reasonably
expected to improve public safety and reduce the suffering of animals.
It appears that manufacturers tend to use the same scientists to do
assessments. Hanlon and co-researchers evaluated the first 600 GRAS notices
submitted during the Interim (FDA Rule) Review period.106 They found that a
relatively small number of scientists were involved in a large number of GRAS
evaluations,107 “suggest[ing] a perceived value in having experts with extensive
GRAS Expert Panel experience in addition to relevant scientific training on the
Expert Panel.”108 Yet, the small number of options may increase the difficulty
for a manufacturer that wants to do animal-free, state-of-the-art safety testing
to find scientists or a product safety testing company willing to do such testing
at a price the manufacturer can justify paying.109 Even so, it is to food
manufacturers’ advantage to use state-of-the-art tests to produce safe food.
Even if a manufacturer completes the testing without notifying FDA and
engaging in prolonged FDA review, as allowed by law, the manufacturer is
running the risk of a finding that the manufacturer has not met its burden under
the law to determine that a substance is GRAS. Further, as food litigation expert
Denis Stearns has written, the best defense for a food producer against
106. Hanlon, Frestedt & Magurany, supra note 50, at 142 (“This article provides a detailed
analysis of the first 600 GRAS Notifications submitted to FDA during the Interim Pilot Program, as
well as the associated warning letters mentioning GRAS during the last 10 + years (i.e., since 2005).”).
107. Hanlon and co-investigators prepared a list of the most commonly used scientists in that
group and the number of GRAS notifications in which they had been involved: Joseph Borzelleca
(148), John Thomas (60), Michael Pariza (58), Robert Nicolosi (48), Madhusudan Soni (48), Richard
Kraska (45), Robert McQuate (45), Walter Glinsmann (41), Stephen Taylor (33), Ian Munro (27),
Stanley Tarka (25), W. Gary Flamm (24), Gary Williams (24), Robert Martin (18), William Waddell
(18), Susan Cho (17), Eric Johnson (17), Robert Kapp (14), Roger Clemens (13), George Fahey (13),
Claire Kruger (12), John Doull (11), Wallace Hayes (11), Douglas Archer (10), Robert Kleinman (10),
and Glenn Sipes (10). Id. at 145.
From [the first] 400 GRAS Notifications, 26 individuals participated in 10 or
more of the GRAS Expert Panels [], and eight of these individuals served on more
than 10% of the GRAS Expert Panels. The most prolific GRAS Expert Panelist
in the first 600 GRAS Notifications was Joseph Borzelleca, who served on 37%,
or 148, of the first 400 GRAS Expert Panels. In addition, at least one individual
from this list of prolific GRAS Expert Panelists served on 88%, or 352 of the first
400 GRAS Expert Panels, with many of the GRAS Expert Panels including
multiple individuals from this list.
Id.
108. Id. at 147.
109. FDA regulations do not prohibit companies from doing in-house safety evaluations, but
they do warn against bias and conflict-of-interest problems and the cost of in-house safety evaluations
might be prohibitive.
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consumer lawsuits “is to sell only safe food.”110 Surely, the fact that companies
like Kellogg’s, Coca-Cola, and General Mills reject animal testing indicates
that it is possible and rational for food producers to use non-animal safety
assessment methods.111 It is also to their advantage if consumers would likely
pay a premium for “cruelty-free” safety assessment, such that the costs and time
spent on such testing are justifiable. In January of 2022, research was conducted
on consumer attitudes toward the use of animal tests in safety assessments of
food ingredients. That research, described in Part III, found that consumers
strongly prefer avoidance of animal testing.
Even if there is considerable consumer preference for non-animal safety
assessments, there is no denying that navigating FDA regulatory waters without
simply following guideline animal test protocols could be daunting. This is
where nonprofit organizations, such as People for the Ethical Treatment of
Animals (PETA) and PETA Science Consortium International e.V. (PSCI), can
become important agents for change through their scientists dedicated to
developing paths forward for companies seeking to avoid animal testing.112
PSCI provides comprehensive information on scientifically sound alternatives
to animal testing.113 Not only does PSCI organize workshops that are highly
attended by regulatory, industry, and academic scientists, it also provides the
following: maintenance of an extensive list of non-animal testing alternatives,
scientific expertise in designing safety assessment protocols tailored to the
specific use of a substance, assistance with securing consultations with the FDA

110. Denis Stearns, A Critical Appraisal of the Impact of Legal Action on the Creation of
Incentives for Improvements in Food Safety in the United States, in FOOD SAFETY ECONOMICS:
INCENTIVES FOR A SAFER FOOD SUPPLY 359, 370 (Tanya Roberts ed., 2018).
111. Kellogg
Company
Animal
Welfare
Commitment,
KELLOGG,
https://crreport.kelloggcompany.com/ppm-animal-welfare-commitment
[https://perma.cc/M85554U7]; Animal Welfare Policy, GEN. MILLS, https://www.generalmills.com/how-we-makeit/healthier-planet/sustainable-and-responsible-sourcing/animal-welfare
[https://perma.cc/K8TBCN4A]; Animal Health and Welfare Guiding Principles, COCA-COLA CO. (June 30, 2020),
https://www.coca-colacompany.com/policies-and-practices/animal-health-and-welfare-guidingprinciples [https://perma.cc/C22R-ZUGT].
112. PETA U.S. and other PETA entities employ approximately 35 scientists. Virtual Interview
with Kathy Guillermo, Senior Vice President, PETA Laboratory Investigations Department, and Jeff
Brown, Science Advisor, PETA Regulatory Testing Department, (July 8, 2020). PETA is not the only
nonprofit organization working to reduce corporate reliance on animal testing. Another example is the
Animal-Free Safety Assessment Collaboration (AFSA), which brings together corporate leaders
(including Proctor and Gamble and ExxonMobil) as well as non-profits (including Humane Society
International and The Humane Society of the United States) to support innovative risk assessment
methods that do not involve animal testing. Home, ANIMAL-FREE SAFETY ASSESSMENT
COLLABORATION, https://www.afsacollaboration.org/ [https://perma.cc/5PEL-SEDH].
113. Alternative Methods Validated for Regulatory Use, PETA SCI. CONSORTIUM INT’L,
https://www.thepsci.eu/alternatives/ [https://perma.cc/33ES-RAH7].
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on the use of non-animal methods prior to conducting new testing for product
approval, and assistance with subsequent FDA inquiries.114 PETA scientists
will assist companies at any stage of the regulatory process.115 This is especially
valuable at the pre-submission stage because the company can work out with
the FDA the type of non-animal safety assessments the FDA will accept for the
specific ingredient, based on information provided by PETA’s scientists. The
FDA actually invites consultation.116
Based on the information provided in this Part, there appear to be several
levers for improving safety and reducing unnecessary suffering of animals. One
is change at the FDA level. Another lies in food manufacturers and their
suppliers insisting that product safety assessment companies ramp up to include
non-animal testing protocols. A third can be found in the interactive
relationship with the FDA through which manufacturers persevere in seeking
FDA acceptance of those methods and increasing FDA receptivity to nonanimal tests without significant delays in approving those tests. Without
internal change at the FDA, it would be a haltingly slow process to use this
method of seeking change in how they approach GRAS and formal reviews of
food additives. For this to happen, there must be entities with scientific
expertise to help companies and the FDA navigate a path to the use of the most
reliable predictive tests in the specific contexts of those companies’ food
ingredients.
Change would occur most quickly if the first move were made by Congress
or the FDA. This could be a comparatively modest move, such as including in
its guidelines more examples of non-animal testing methods. Or it could take
the form of bold change by the FDA, such as requiring explicit pre-approval for
use of animal tests but only detailed written justification for non-animal tests
used by the manufacturer. While some food manufacturers might be able to
persuade the FDA that its proposed animal tests would be appropriate, the
burden should still be on them to prove the reliability of predicting harm to
consumers because they might well be using the least appropriate or up-to-date
methods for food safety assessment. Moreover, this pre-approval requirement
is consistent with the “3Rs” principle of humane research—refinement,
114. PETA INT’L SCI. CONSORTIUM LTD., WORKFLOW FOR EVALUATING FOOD INGREDIENT
SAFETY 1 (2019) https://www.piscltd.org.uk/wp-content/uploads/2019/10/Food-Ingredient-SafetyFactsheet.pdf [https://perma.cc/C85E-GQEX].
115. Home, PETA SCI. CONSORTIUM INT’L, https://www.thepsci.eu/ [https://perma.cc/4QPQL5E8].
116. “FDA encourages individuals to thoroughly review its GRAS notification submission
procedures prior to sending a notification to the agency. Additionally, a notifier may request a presubmission meeting with FDA to discuss issues that may be relevant to the submission of the notifier’s
GRAS notice.” U.S. FOOD & DRUG ADMIN., supra note 82.
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reduction, and replacement of animal use in experiments.117 The 3Rs has been
a feature of the federal Animal Welfare Act since it was amended in 1985.118
Accordingly, the FDA should require a showing that animal tests are necessary.
At the level of legislative influences leading to change, the FDA
Modernization Act 2.0119 could be significant. While specific to allowing
pharmaceutical companies to bypass animal testing prior to human trials of
pharmaceuticals, this Act would signal support for reduced reliance on animal
testing.120
The FDA already allows non-animal tests in the novel food ingredient
context, but this law could promote a useful cultural shift in the agency, which
could enhance FDA’s receptivity to non-animal testing for food safety
testing.121 In turn, FDA’s approval of alternative test methods, its publication
of acceptable non-animal protocols, and its willingness to promptly review nonanimal-based tests without bias would boost manufacturer confidence in using
non-animal alternatives. If their statements can be taken at face value, it appears
that some members of the industry are ready for alternatives but are waiting for
FDA to assure them that these tests will be acceptable.122 That is why the
117. Here, the issue is replacement with non-animal tests. The other Rs focus on refinement of
experiments to require less distress imposed on animals and reduction in the number of animals used
in an experiment. W.M.S. RUSSELL & R.L. BURCH, THE PRINCIPLES OF HUMANE EXPERIMENTAL
TECHNIQUE ch. 4 (1959), https://caat.jhsph.edu/principles/chap4d [https://perma.cc/4Y6T-U5SR].
118. 7 U.S.C. § 2143(e).
119. S. 5002, 117th Cong. (2022).
120. See supra notes 39–40 and accompanying text.
121. Similarly, the Environmental Protection Agency’s multi-faceted plan for reducing the use
of vertebrate animals in chemical testing signals a change in thinking about testing on animals. EPA
New Approach Methods: Efforts to Reduce Use of Vertibrate Animals in Chemical Testing, U.S. ENV’T
PROT.
AGENCY,
https://www.epa.gov/research/epa-new-approach-methods-efforts-reduce-usevertebrate-animals-chemical-testing [https://perma.cc/B9EL-T7GG]. It would be unfortunate if testing
simply shifts to invertebrate animals because science is revealing that invertebrate animals suffer, and
it is not clear that testing on invertebrates would be any more reliable than testing on vertebrate animals.
All this signals is that an agency is considering alternatives to its business-as-usual model of animal
testing.
122. See, e.g., Comments from Biotech. Indus. Org., Calorie Control Council, Grocery Mfrs.
Ass’n, and Unilever, FDA Docket No. FDA-2014-N-1497: Toxicological Principles for the Safety
Assessment of Food Ingredients; Public Meeting on Updates and Safety and Risk Assessment
Considerations (Request for Comments, Oct. 30, 2014), https://www.regulations.gov/docket/FDA2014-N-1497/comments. In contrast, there are several companies that state that they are for alternatives
to animal testing but recommend against including alternatives in FDA guidance before they are
validated. See, e.g., Comments from Am. Frozen Food Inst., Int’l Food Additives Council, Int’l Life
Scis. Inst. N. Am., and even Grocery Mfrs. Ass’n, FDA Docket No. FDA-2014-N-1497, Toxicological
Principles for the Safety Assessment of Food Ingredients; Public Meeting on Updates and Safety and
Risk
Assessment
Considerations
(Request
for
Comments,
Oct.
30,
2014),
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involvement of nonprofit animal protection organizations in identifying reliable
non-animal testing methods and seeking FDA acknowledgement of their value
can be so important.123 The key to improved public health and safety and
reduced animal suffering (another public value) is reliance on state-of-the art
safety assessments, which are often faster and less costly than animal tests.124
PART II. CONSUMER FOOD PRODUCT SAFETY LITIGATION
Is there any other reason for a food manufacturer such as Impossible to do
animal-based safety testing? What about avoidance of exposure to liability from
consumer food safety lawsuits? The purpose of this Part is to explain why a
reasonably risk-averse manufacturer would not pursue animal testing to reduce
exposure to a consumer safety lawsuit, such as a consumer claiming injury from
Impossible’s novel food ingredient, GE heme. There are two reasons. First,
such suits are rare and have low odds of success, primarily due to the difficulty
of proving causation.125 If as toxic tort litigator Lawrence G. Cetrulo states,
“Toxic tort litigation involving injuries from hazardous chemical contaminants
in food [against the food industry] is still in its infancy,”126 the odds of such a
suit regarding a substance not even identified as toxic would seem quite low.
Second, animal test data would not reliably protect companies from liability
because courts are skeptical about the validity and “fitness” of data derived
from animal testing as a basis for evidence submitted by expert witnesses.
Part II.A. explores the first reason, and Part II.B. is focused on the second.
A. Extent of Litigation and Liability Exposure
A consumer who believes they have been harmed by a food manufacturer
might start by considering federal laws that protect consumers from injurious
food products. Indeed, there are several. However, while consumers can report
complaints about food producers under such laws as the Food, Drug &

https://www.regulations.gov/docket/FDA-2014-N-1497/comments. It is difficult, therefore, to parse
out what such industry actors would actually support, but their at least outward support of non-animal
alternatives could still be used as leverage in support of such tests.
123. See supra notes 43–44, 110.
124. Lucy Meigs, Lena Smirnova, Costanza Rovida, Marcel Leist & Thomas Hartung, Animal
Testing and Its Alternatives—The Most Important Omics Is Economics, 35 ALTEX 275, 275 (2018)
(“Only more recently has the economic view begun to have an impact: Many animal tests are simply
too costly, take too long, and give misleading results.”).
125. Denis Stearns, On (Cr)edibility: Why Food in the United States May Never Be Safe, 21
STAN. L. & POL’Y REV. 245, 249 n.12 (2010) (noting that the difficulty of tracing an illness back to
the producer of the food reduces producer incentives to invest in improved safety).
126. 4 LAWRENCE G. CETRULO, Toxins in Food and Associated Litigation, in TOXIC TORTS
LITIGATION GUIDE, 2021-2022, at § 39:45 (2021).
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Cosmetic Act (FDCA),127 the Food Safety Modernization Act (FSMA),128 and
the Nutrition Labeling and Education Act (NLEA),129 they cannot directly
enforce the provisions of those federal laws through private lawsuits.130 The
FDA holds that authority, though these laws also allow for coordinated state
action.131 Not only does the FDA hold enforcement power, but federal law
preempts most state law food safety claims. Nevertheless, a few state law
claims survive preemption132 and, according to the Food and Drug Law Institute
(FDLI), “litigants have employed a variety of approaches premised on state
consumer protection statutes to indirectly bring the FDCA into play.”133 None
of the examples raised by the FDLI deal with toxicity or allergenicity of food
substances. However, FSMA might seem most promising to consumers
claiming injury because it concerns food safety. According to food lawyer Kim
Bousquet,
As a result of these new [consumer safety protective]
requirements [in the FSMA] and increased documentation
demands, plaintiff’s attorneys will soon be able to look to a
facility’s compliance program and easily determine whether
the company complied with its own safety plan and with the
FSMA’s stringent standards. They can then argue, based on the
company’s well-documented efforts, that it failed to meet a
state common law (or statutory) standard of care. Company
127. Food, Drug & Cosmetic Act, 21 U.S.C. §§ 301–92.
128. Food Safety Modernization Act, Pub. L. No. 111-353, 124 Stat. 3885 (2011) (codified as
amended in scattered sections of 21 U.S.C.).
129. Nutrition Labeling and Education Act of 1990, Pub. L. No. 101-535, 104 Stat. 2353
(codified as amended in scattered sections of 21 U.S.C.).
130. The FSMA and the NLEA are amendments to the FDCA. There is no private right of action
under the FDCA. MICHAEL T. ROBERTS, FOOD LAW IN THE UNITED STATES 304 (2016) (citing
Murphy v. Cuomo, 913 F. Supp. 671, 679 (N.D.N.Y. 1996) (denying standing to plaintiff to bring an
action based on the FDCA)).
131. Regarding the FDCA, the specific language can be found at 21 U.S.C. § 337(a) (“[A]ll such
proceedings for the enforcement, or to restrain violations, of [the FD&C Act] shall be by and in the
name of the United States.”). See Murphy, 913 F. Supp. at 679 (citing Merrell Dow Pharmaceuticals
v. Thompson, 478 U.S. 804, 811 (1986) (denying standing to plaintiff to bring an action based on the
FDCA)). Regarding the FSMA, which applies only to foods regulated by the FDA, the FDA has
authority for enforcement. 21 U.S.C. § 350h(d) (“The Secretary may coordinate with the Secretary of
Agriculture and, as appropriate, shall contract and coordinate with the agency or department designated
by the Governor of each State to perform activities to ensure compliance with this section.”). Regarding
the NLEA, specific language can be found requiring the Secretary of the FDA to be notified about
states enforcing provisions of the NLEA. 21 U.S.C. § 337(b)(2).
132. ROBERTS, supra note 130, at 35–36 (describing generally federal preemption laws that
nevertheless allow for consumer litigation in some cases).
133. Theodora McCormick, Food and Supplement Class Action Suits That Rely on Alleged
Regulatory Violations, FOOD & DRUG L. INST., Aug. 2021 at 12, 12.
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compliance records, consequently, could be used to support
viable claims for foodborne illness . . . .134
If sued on a state law consumer protection theory, a company’s first defense
would be that the state law had been preempted by federal laws consumers
cannot use directly to file lawsuits.135 Indeed, Cetrulo states that “in the limited
number of food contaminant cases to date, defendants have relied on
preemption defenses to defeat the plaintiff’s failure to warn claims.”136
Nevertheless, in the case of claims for liability from harm allegedly caused by
novel food ingredients or additives used by, say, a hypothetical client company
producing meat analogues, it appears on first review that some state claims
could survive preemption.137 A particularly risk-averse company would be
interested in considering whether and to what extent the company could be
vulnerable to a consumer lawsuit based on state law and, secondarily, how best
to defend itself if such a lawsuit went forward. State law varies, but types of
claims that could be applicable in some states in some cases include negligence
and strict liability torts, contracts, and commercial causes of action.138 Cetrulo
claims that plaintiffs rely most heavily on allegations of failure to warn,139 but
many of these would be pled in the alternative and with similar analysis.140 The
focus in the first section of this Part is how vulnerable a company is to the risk
of successful state law claims.
I. Tort Claims
A few different theories animate products liability cases, including
manufacturing defects, design defects, and warning defects. In tort-based food
134. Kim Bousquet, Is the FSMA a Plaintiff’s Lawyer’s Dream and a Food Industry Nightmare?,
THOMPSON COBURN LLP (Dec. 21, 2016), https://www.thompsoncoburn.com/insights/blogs/lifesciences-decoded/post/2016-12-21/is-fsma-a-plaintiff-s-lawyer-s-dream-and-the-food-industry-snightmare [https://perma.cc/A9YH-UR5Q].
135. ROBERTS, supra note 130, at 35–36 (describing generally federal preemption laws that
nevertheless allow for consumer litigation in some cases).
136. CETRULO, supra note 126, at § 39:46.
137. ROBERTS, supra note 130, at 35–36.
138. According to food law scholar Michael T. Roberts, “[C]onsumers made sick from eating
unsafe food may recover damages from manufacturers or sellers of the unsafe food in actions brought
under one or more theories of liability, including strict liability in tort, breach of implied warranty, and
negligence.” ROBERTS, supra note 130, at 197 (citing Porrazzo v. Bumble Bee Foods, LLC, 822 F.
Supp. 2d 406 (S.D.N.Y. 2011)).
139. CETRULO, supra, note 126, at § 39:45.
140. See Katharine Van Tassel, The Introduction of Biotech Foods to the Tort System: Creating
a New Duty to Identify, 72 U. CIN. L. REV. 1645, 1668–77 (2004) (concerning biotech foods but also
providing an overview of state law causes of action). Van Tassel notes that “[c]urrent product liability
law is actually an amalgamation of tort and contract theories.” Id. at 1672 n.141. (describing overlap
in torts causes of action in food product liability litigation).
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liability cases, analysis of these causes can overlap when courts are actually
conducting the analysis.141 As an initial matter, courts “have historically used
two tests: the foreign-natural test and the reasonable-consumer-expectations
test.”142 A minority of courts apply a test focused on whether the defect in the
food was a foreign object (such as a piece of glass) or natural object (such as
pieces of shell in a package of shelled nuts).143 These courts assign no liability
for defects that are natural to the food product regardless of the care producers
exercised during product development and production.144 Presumably, a
customer would know to expect the possibility of shell fragments in a package
of nuts but would not be expecting fragments of glass. Most courts have moved
away from this categorical distinction—natural and foreign—in the direction
of a more flexible “reasonable consumer” standard.145 In the case of the nutshell
fragments, this “reasonable consumer” standard would result in the same
analysis and outcome as a “natural” versus “foreign” object test. The
“reasonable consumer” standard avoids only the prior categorization of
something as “foreign” or “natural.” This reasonable consumer standard is
articulated in The Restatement (Third) of Torts: Products Liability section 7,
through the example of a chicken bone in a chicken enchilada. “Although a oneinch chicken bone may in some sense be ‘natural’ to a chicken enchilada,
depending on the context in which consumption takes place, the bone may still
be unexpected by the reasonable consumer, who will not be able to avoid injury,
thus rendering the product not reasonably safe.”146
In the case of a plant-based burger, a “reasonable consumer” might not
expect an ingredient to have originated in a genetically modified organism or
an ingredient derived from an animal product, for instance. This is where
analysis would typically include consideration of labeling law, which is largely
regulated at the federal level. However, as will be considered below as to
141. See id. at 1680 n.163, 1683 (“The idiosyncratic plaintiff defense plays in the analysis for
both design defects and failures to warn. . . . The injured consumer faces the same insurmountable
hurdle in seeking to establish liability for the failure to warn as she faced with attempting to establish
liability based on either a manufacturing [defect] or defective design.”).
142. ROBERTS, supra note 130, at 199.
143. Id. at 199–200 (citing Mix v. Ingersoll Candy Co., 59 P.2d 144 (Cal. 1936) (holding that a
reasonable consumer would anticipate the presence of chicken bone fragments in a prepared chicken
potpie and that such a potpie would be fit for human consumption). But see RESTATEMENT (THIRD)
OF TORTS: PRODUCTS LIABILITY § 7 cmt. b (AM. L. INST. 1998) (articulating when a chicken bone
fragment might not be anticipated by a reasonable consumer).
144. ROBERTS, supra note 130, at 199.
145. ROBERTS, supra note 130, at 200.
146. RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 7 cmt. b (AM. L. INST. 1998).
See also Van Tassel, supra note 140, at 1674–77 (providing a more in-depth discussion of the general
framework).
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commercial “unfair or deceptive trade” claims, some state law-based labeling
claims could survive federal preemption. Resolution of preemption claims
requires fact-specific analysis, making prediction of outcome difficult in some
cases.147
What about vulnerability under a negligence claim? For such a claim to
succeed, the plaintiff bears the burden to establish that the defendant had a duty
to exercise reasonable care and failed to do so, with resultant injury to the
plaintiff.148 In the case of a plant-based burger, the claim would be that the
company was negligent in a way that resulted in consumer harm from
consuming the company’s burger, such as Impossible’s burger containing GE
heme. Recovery for injury from exposure to novel food ingredients is unlikely
under the tort system for several reasons. First, it isn’t clear that consumers
would know that there was a novel food ingredient; ingredient lists often
contain long lists of unfamiliar ingredients.149 A 2017 survey of more than
1,000 consumers found that most “feel confused at least some of the time about
ingredients listed on food package labels,” and many are “concerned when they
eat food products that contain ingredients that they don’t understand.”150
Second, under negligence, a plaintiff must establish that a producer should have
foreseen risk as well as prove causation,151 both of which can be difficult. This
is especially true for novel food ingredients, such as genetically modified
ingredients, where risk assessment in human populations can lag behind
production and distribution.152 However, while the company might claim that
compliance with FDA requirements should be the basis for the decision, a
determined plaintiff could argue that the FDA standard is different, and at least
one court has taken that position in the context of pharmaceutical companies’
safety assessments.153 The knowledge available about a novel ingredient at the
time of its FDA-required premarket safety assessment may be far less than
147. See, e.g., Wyeth v. Levine, 555 U.S. 555 (2009). The Court found no preemption by the
FDA in the context of a state failure to warn claim against a pharmaceutical manufacturer. Id. at 581.
It was differentiated by the case PLIVA, Inc. v. Mensing, where the Court found preemption in a very
similar case regarding generic drugs. PLIVA, Inc. v. Mensing, 564 U.S. 604, 609 (2011).
148. ROBERTS, supra note 130, at 203.
149. Label Insight, Confusing Ingredients Cause Shoppers to Consider Switching Brands Even
if it Means Paying More, FOOD MFG. (June 28, 2017), https://www.foodmanufacturing.com/
labeling/news/13165312/study-confusing-ingredients-cause-shoppers-to-consider-switching-brandseven-if-it-means-paying-more [https://perma.cc/CM4E-WDYZ].
150. Id.
151. ROBERTS, supra note 130, at 202.
152. See Van Tassel, supra note 34, at 247.
153. Soldo v. Sandoz Pharms. Corp., 244 F. Supp. 2d 434, 513 (W.D. Pa. 2003) (stating that
FDA’s premarket assessment “is based on a different standard than tort law-based scientific proof of
causation”).
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knowledge that accumulates as people actually purchase and consume a
product.154
Significant obstacles for the consumer-plaintiff in establishing causation
are defendants’ potential ability to argue that a product became defective
through the actions of others in the supply chain, that the harm might have been
caused by other foods plaintiff consumed, or that a plaintiff’s response is
idiosyncratic or the result of plaintiff’s mishandling of the product.155
Accordingly, it may be quite difficult to show that but for consumption of a
specific product or a specific ingredient in a product, the plaintiff would not
have suffered harm.156 Even if a plaintiff’s reaction occurs soon after
consuming the product, it can be difficult to prove causation.157 If a plaintiff has
an allergic or toxic response to a food that is ordinarily safe, their claim may be
rejected as insufficient to establish liability because the plaintiff’s response was
idiosyncratic or unrelated to their consumption of the product.158
“Failure to warn” is a type of products liability claim that alleges that the
manufacturer failed to alert the consumer of a foreseeable risk while using the
product for its intended purpose. The Restatement (Third) of Torts imposes

154. See id. at 542–43 (“This Court concludes that FDA does not—and the scientific community
cannot—utilize postmarketing surveillance in assessing causation.”). Impossible began accumulating
information early on because it had begun marketing its burger in restaurants, including fast food and
chain restaurants, before it sought an FDA “no questions” letter. Impossible’s use of heme was reported
in 2015. Yasmin Tayag, The Meat Lover’s Guide to Heme, the Protein That Makes Everyone Crave
Blood, INVERSE (Sept. 4, 2015), https://www.inverse.com/article/5948-the-meat-lover-s-guide-toheme-the-protein-that-makes-everyone-crave-blood [https://perma.cc/TC72-54YH]. Impossible
launched the burger for the first time in 2016, first at a restaurant in New York City and then in west
coast restaurants. Christina Troitino, The Impossible Burger’s West Coast Debut and the Wild Frontier
of Plant-Based Meat, FORBES (Oct. 13, 2016), https://www.forbes.com/sites/christinatroitino
/2016/10/13/the-impossible-burgers-west-coast-debut-and-the-wild-frontier-of-plant-basedmeat/?sh=fca4fd5cd8c1 [https://perma.cc/7MKM-2K65]. Impossible began conducting tests on
animals in 2017 through a contract with Product Safety Labs. IMPOSSIBLE FOODS INC., GRAS NOTICE
NO. 737, GRAS NOTIFICATION FOR SOY LEGHEMOGLOBIN PROTEIN PREPARATION DERIVED FROM
PICHIA PASTORIS 26, 28, 30, 31 (2017), https://www.fda.gov/media/124351/download
[https://perma.cc/BMD9-3HVQ].
155. ROBERTS, supra note 130, at 205; see also Van Tassel, supra note 140, at 1680–81
(concerning idiosyncratic plaintiffs bearing responsibility for harm that occurs due to their ingestion
of a substance that does not generally cause allergic reactions).
156. See Stearns, supra note 125.
157. ROBERTS, supra note 130, at 202–03.
158. See Stearns, supra note 110 (reporting that his firm had represented thousands of victims
of foodborne illnesses but that only three went to trial and only one went to the jury because of the
difficulty of proving causation); Van Tassel, supra note 140, at 1679. But specifically as to “failure to
warn” cases, see CETRULO, supra note 126, § 39:46 (“[I]n the limited number of food contaminant
cases to date, defendants have relied on preemption defenses to defeat the plaintiff’s failure to warn
claims.”).
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liability on defendants who, knowing of a danger, fail to provide reasonable
warnings or instructions.159 The elements of a failure to warn claim vary by
jurisdiction but, when brought under a negligence theory, typically include the
general tort requirements of duty, breach of duty, causation, and actual injury.160
A consumer alleging injury from consuming a novel food ingredient they had
no reason to expect in the food product might well argue that testing the
ingredient would have uncovered the potential risk to consumers such that the
“duty to warn” would have arisen. Certainly, food producers have a legal
obligation to assess the safety of their novel ingredients, and failure to do so
could lead to liability if causation were established. The issue is what type of
testing would most reliably protect the company. There are various non-animal
tests that can satisfy this requirement.161
Strict liability, on the other hand, requires showing only that the product
was defective in some way and that the defect caused the harm to the plaintiff.162
While this requires satisfaction of fewer elements, a difficult challenge remains:
establishing a causal link between consumption of the specific substance and
the harm to the consumer.163
Consider the case of Watson v. Dillon Companies,164 in which a consumer
brought claims against a microwave popcorn manufacturer alleging that his
respiratory disorders were caused by flavoring ingredients in the defendant’s
product.165 Diacetyl, the specific chemical in the flavoring alleged to cause
harm, was listed as GRAS for oral consumption, but exposure in this case was
through inhalation.166 The plaintiff brought product liability claims for
negligence, strict liability, failure to warn, and a violation of the Colorado
Consumer Protection Act (CCPA).167 The Watson court found that because the
popcorn manufacturer was aware of the health effects on workers from
exposure to diacetyl in popcorn manufacturing plants, “[a] reasonable jury
159. RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 2 (AM. L. INST. 1998) (“A
product is defective when, at the time of sale or distribution, it contains a manufacturing defect, is
defective in design, or is defective because of inadequate instructions or warnings.”); see also W. PAGE
KEETON, DAN B. DOBBS, ROBERT E. KEETON & DAVID G. OWEN, PROSSER & KEETON ON THE LAW
OF TORTS § 99, at 697 (5th ed. 1984).
160. W. P. KEETON, DOBBS, R. KEETON & OWEN, supra note 159, at 164–65.
161. See Ingber, supra note 43.
162. ROBERTS, supra note 130, at 197–99.
163. Id. at 202.
164. 797 F. Supp. 2d 1138 (D. Colo. 2011).
165. Id. at 1147.
166. Id. at 1144 (“Although the U.S. Food and Drug Administration categorizes diacetyl as
‘GRAS,’ or ‘Generally Recognized as Safe,’ this label apparently concerns eating or consumption, and
does not necessarily mean that the chemical is safe to inhale.” )(citing an expert witness’s report).
167. Id. at 1149.
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could find that given the magnitude of the harm and the lack of information
about the minimum exposure level capable of causing harm, the manufacturer
acted recklessly in failing to investigate or warn consumers of the potential for
harm.”168
In Watson, the court broke causation into two parts: first, the substance must
be capable of causing the particular injury alleged, and second, the substance
must have actually caused the plaintiff’s injury.169 The court articulated four
elements that may help in establishing specific causation: “(1) the toxic
substance at issue has been demonstrated to cause in humans the disease or
illness suffered by the plaintiff; (2) the individual has been exposed to a
sufficient amount of the substance in question to elicit the health effect at issue;
(3) the chronological relationship between exposure and effect is biologically
plausible; and (4) the likelihood that the chemical caused the disease or illness
is considered in the context of other known causes.”170 Animal testing data
could be relevant as to (3) and (4), but for reasons discussed in the next section,
data derived from animal testing are not considered reliable by many courts.
The Watson court did not find plaintiff’s expert’s evidence based on animal
studies to be inadmissible, but the court relied heavily on the plentiful
epidemiological data as a reason for admissibility of the expert’s opinion
regarding causation.171
Consumer claims about unsafe food may also be brought under specific
statutes of a given jurisdiction.172 In the Toxic Torts Litigation Guide, Cetrulo
points to California’s Safe Drinking Water and Toxic Enforcement Act of 1986,
also known as Proposition 65 (Prop. 65), as a primary arena of litigation.173
California’s Prop. 65 allows suits against manufacturers who fail to provide
consumers warning of exposure to any chemical known to the state to cause

168. Id. at 1162.
169. Id. at 1149.
170. Id. (citing Henricksen v. ConocoPhillips Co., 605 F. Supp. 2d 1142, 1156 (E.D. Wash.
2009)).
171. Id. at 1154. (“Given the significant evidence of the toxicity of diacetyl and the
epidemiological studies showing health effects from inhalation of butter flavoring ingredients
containing diacetyl, I conclude that Dr. Egilman should be permitted to opine regarding general
causation.”).
172. See California v. Frito-Lay, Inc., 2008 WL 4108102 (Cal. Super. 2008) (verdict and
settlement summary); Sciortino v. Pepsico, Inc., 108 F. Supp. 3d 780 (N.D. Cal. 2015) (finding that
Prop. 65 was not preempted and that consumer plaintiff could proceed on claim based on failure to
warn of a known carcinogen in soft-drink products); Fellner v. Tri-Union Seafoods, L.L.C., 539 F.3d
237 (3d Cir. 2008) (finding plaintiff was not preempted from bringing a claim for failure to warn of
risks of consuming shellfish product, based on New Jersey Products Liability Act).
173. CETRULO, supra note 126, at § 39:47.
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cancer or reproductive harm.174 Failure to warn claims survive under Prop. 65,
and are not preempted, because of the savings clause in the NLEA carving out
an exception for warnings concerning food safety.175 Accordingly, there is some
minimal risk of exposure to liability if a new food ingredient falls within the
scope of Prop. 65, but then the question, discussed in Part II.B. below, is
whether data derived from animal testing would provide admissible evidence.
II. Contract: Breach of Warranty
As an alternative theory to tort law, a consumer might want to make the
contract claim of “breach of warranty” if the consumer is claiming injury from,
say, ingestion of a plant-based burger in which an ingredient sourced from a
genetically modified organism could not be anticipated without warning. An
express warranty is one that is clearly communicated to the consumer, usually
through writing, while an implied warranty of merchantability represents that
the goods were of merchantable quality.176 The exact requirements vary by
jurisdiction, but in the food context, a manufacturer is typically required to
provide food products fit for their intended use to a reasonable consumer.177
Formulated this way, the analysis of these claims would overlap with tort
analysis.178 The courts often speak to whether a product was “wholesome” and

174. CAL. HEALTH & SAFETY CODE § 25249.6 (West 2022).
175. The preemption provisions of the NLEA do not “apply to any requirement respecting a
statement in the labeling of food that provides for a warning concerning the safety of the food or
component of the food.” NLEA, Pub. L. No. 101-535, 104 Stat. 2364 (codified at 21 U.S.C. § 343–1).
For a case that involved no preemption, see Sciortino v. Pepsico, Inc., 108 F. Supp. 3d 780 (N.D. Cal.
2015). However, in some cases, failure to warn claims are found to be preempted, particularly when it
comes to warnings on labels that are not required by the FDA. See, e.g., Cardinale v. Quorn Foods,
Inc., 2011 WL 2418628 (Conn. Super. Ct. 2011) (holding that claims based on failure to warn of
dangers in food product were preempted by FDA’s labeling requirements); Mills v. Giant of Md., LLC,
441 F. Supp. 2d 104 (D.D.C. 2006) (holding that FDCA preempted negligence and product liability
claims based on failure to warn of harm to a lactose intolerant plaintiff from consuming dairy products).
The FDCA contains three other preemption provisions on non- prescription drugs, 21 U.S.C. § 379r,
medical devices, 21 U.S.C. § 360k, and cosmetics, 21 U.S.C. § 379s. In the case of both nonprescription drugs and cosmetics, the preemption expressly doesn’t affect actions under state products
liability law. E.g., 21 U.S.C. § 379r(e). All of the above-mentioned preemption provisions allow the
Secretary of the FDA to create an exemption upon petition by the state. In the case of non-prescription
drugs, the state requirement must “protect an important public interest that would otherwise be
unprotected, including the health and safety of children.” 21 U.S.C. § 379r(b)(1)(A).
176. U.C.C. § 2-314 (AM. L. INST. & UNIF. L. COMM’N 1977).
177. See Backus v. Gen. Mills, Inc., 122 F. Supp. 3d 909, 933 (N.D. Cal. 2015) (finding that
plaintiff failed to state a breach of implied warranty claim where the amount of injurious ingredient at
issue in baking mixes was not of the amount to “render[] them totally unfit for their intended use”).
178. See generally Watson v. Dillon Cos., 797 F. Supp. 2d 1138 (D. Colo. 2011). See also Van
Tassel, supra note 140, at 1672 n.141, 1685 n.180.
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“fit for human consumption,” and apply either the foreign/natural object test or
the reasonable consumer test as discussed above.179
Under breach of warranty analysis, a producer can be held liable for
products that are “unmerchantable.”180 A consumer would not have to establish
negligence or fault on the part of the producer to recover damages under this
theory, but merely that the producer sold the unmerchantable food and that the
consumer’s illness was caused by the aspect of the food that made the product
unfit.181 Thus, this contract-based test of “unmerchantable” is nearly identical
to that found for assessment of tort liability grounded in injury from which a
“reasonable consumer” could not protect themselves.182 In the hypothetical
situation of claiming injury from ingestion of a plant-based burger with an
ingredient produced from a genetically modified organism, a plaintiff would
have to argue successfully that any reasonable consumer—not just the
plaintiff—would not expect such an ingredient to exist in their plant-based
product.
III. Unfair or Deceptive Trade Practices
A claim for unfair trade practices may be argued under specific consumer
protection laws of a jurisdiction. The legal requirements to bring such a claim
and analysis of these claims vary by jurisdiction but typically turn on whether
a manufacturer created a substantial danger to consumers and failed to
adequately inform them.183 Under federal law, “unfair or deceptive acts or
practices in or affecting commerce[] are . . . unlawful.”184 In addition, many
states have individual consumer protection statutes, with requirements that vary
by jurisdiction.185 In general, these laws exist to protect consumers from unfair
and unconscionable business practices that are likely to cause the consumer
harm, which they cannot reasonably avoid, or when a representation or
omission is likely to deceive or mislead a consumer in some meaningful way.186
These claims, similar to the contract claims discussed above, are frequently

179. ROBERTS, supra note 130, at 204–05.
180. U.C.C. § 2-314 (AM. L. INST. & UNIF. L. COMM’N 1977).
181. ROBERTS, supra note 130, at 204–05.
182. See Sean M. Flower, Is Strict Product Liability in Tort Identical to Implied Warranty in
Contract in the Context of Personal Injuries?, 62 MO. L. REV. 381, 388–89 (1997).
183. Van Tassel, supra note 140, at 1685 (“There can be no negligence in the failure to warn
about a risk in the absence of evidence that would justify a finding that a manufacturer or other seller
knew or in the exercise of ordinary care should have known about the risk.”).
184. 15 U.S.C. § 45(a)(1).
185. ROBERTS, supra note 130, at 304.
186. Id. at 304–06.
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brought in the alternative, and the analysis blends with torts, contracts, and
failure to warn.187
Many of the cases regarding deceptive trade practices allege issues with the
labeling of food products. These cases are frequently preempted by FDA
regulations regarding labeling of food.188 However, even when it comes to the
highly, federally regulated field of labeling, some labeling claims have survived
preemption. In one such case about the use of “natural” on a product’s label,
the court held that the FDA had not established standards for use of “natural”
and had not explicitly preempted states’ ability to define “natural” for sales of
products in their jurisdictions.189 There are other instances of surviving a
manufacturer’s preemption labeling challenge, but all such cases show that
there is considerable reliance on analysis of the specific factual circumstances
of each situation. 190 A risk-averse company would analyze state laws that
define “natural” or “organic” or “plant-based” to determine the company’s level
of vulnerability and then label the product accordingly. If a non-GMO food
product is labeled as “natural” in violation of a state law that defines “natural”
in a specific way, there could be a challenge, but it is not a challenge that would
most likely require animal testing to refute.
This Article has used Impossible’s use of GE heme as an example, so it is
appropriate to consider GMO labeling requirements in somewhat more detail.
Consumers have been wary of foods containing GMOs,191 but the FDA has
187. See generally Watson v. Dillon Cos., 797 F. Supp. 2d 1138 (D. Colo. 2011).
188. See Beasley v. Lucky Stores, Inc., 400 F. Supp. 3d 942 (N.D. Cal. 2019); Beasley v.
Conagra Brands, Inc., 374 F. Supp. 3d 869 (N.D. Cal. 2019); Hawkins v. Kellogg Co., 224 F. Supp.
3d 1002 (S.D. Cal. 2016).
189. Hilsley v. Gen. Mills, Inc., 376 F. Supp. 3d 1043, 1051 (S.D. Cal. 2019) (holding some
claims regarding deceptive “natural” labels on fruit snacks were not preempted by FDA regulations).
190. See Colella v. Atkins Nutritionals, Inc., 348 F. Supp. 3d 120 (E.D.N.Y. 2018) (holding
NLEA preempted some, but not all, claims regarding deceptive low or no net carbs labels); Garcia v.
Kashi Co., 43 F. Supp. 3d 1359 (S.D. Fla. 2014); Simpson v. Cal. Pizza Kitchen, Inc., 989 F. Supp. 2d
1015 (S.D. Cal. 2013).
191. Kevin T. Higgins, What Do Consumers Think of GMOs?, FOOD PROCESSING (June 7,
2018),
https://www.foodprocessing.com/product-development/gmos/article/11313385/what-doconsumers-think-of-gmos [https://perma.cc/55RZ-DHTE] (finding that the overwhelming majority of
consumers know about GMOs, that consumers have been less willing over time to purchase
conventionally grown produce, and that they are increasingly relying on organic foods to reduce
possible exposure to GMO foods); Cary Funk & Meg Hefferon, Most Americans Accept Genetic
Engineering of Animals That Benefits Human Health, but Many Oppose Other Uses, PEW RECH. CTR.
(Aug. 16, 2018), https://www.pewresearch.org/science/2018/08/16/most-americans-accept-geneticengineering-of-animals-that-benefits-human-health-but-many-oppose-other-uses/
[https://perma.cc/ZY2Q-DLZX] (finding that American respondents to survey were least likely to
approve uses that provided little benefit, such as altering aquarium fish so that they would glow, and
most likely to approve uses that benefit humans, such as altering mosquitoes’ reproductive capacity in
order to limit spread of disease).

BRYANT_21NOV22 (DO NOT DELETE)

2022]

NOVEL FOOD INGREDIENTS

137

treated genetically engineered ingredients—even those that involve the
insertion of genetic material from animals into plants—the same as ingredients
produced by conventional plant hybridization techniques, and food producers
have had no obligation to label products that include them.192 While regulation
of these ingredients may not change, new federal regulations regarding
“bioengineered” food labeling (called the National Bioengineered Food
Disclosure Standard) were published by the U.S. Department of Agriculture in
2018, and compliance became mandatory on January 1, 2022.193 Prior to
January 1, 2022, it was possible to argue that customers would be unlikely to
bring causes of action based on an alleged injury from a GMO ingredient
because they were unlikely to know of the existence of a GMO ingredient in a
particular food product.194 Consumer awareness of GMO ingredients may
change in the aftermath of the new federal “bioengineered” labeling
requirements, but critics of the law contend that there are hurdles to consumers
learning about a GMO ingredient195 and many loopholes that allow food
producers to avoid labeling their products as containing GMO ingredients 196
There might be an argument that state law should apply to products falling
within such a loophole, but much would turn on how a court would evaluate the
different bases of federal preemption of a state statute under the National
Bioengineered Food Disclosure Standard.197
192. See Van Tassel, supra note 34, at 223, 229–30, 237–42. Van Tassel notes that lack of
consumer information means that consumers cannot make reasonable choices based on knowledge that
the ingredients they are consuming are genetically modified. Id. at 238, 247.
193. National Bioengineered Food Disclosure Standard, 83 Fed. Reg. 65814 (Dec. 21, 2018)
(codified at 7 C.F.R. pt. 66).
194. Food producers could choose to label their products as “non-GMO,” but a producer that
provided no labeling regarding GMO ingredients was not violating labeling laws, and nothing could
be inferred from silence on the label. Van Tassel, supra note 140, at 1655, 1681–82.
195. See Keller and Heckman, LLP, Legal Challenge to BE [Bioengineered] Food Disclosure
Standard, NAT. L. REV. (Jan. 4, 2022), https://www.natlawreview.com/article/legal-challenge-to-befood-disclosure-standard [https://perma.cc/JV7J-RLZQ]. Among other complaints, several food
producers and organizations fault the QR code option for disclosure of BE foods. Id. Not all customers
have smartphones capable of reading the codes, and even those who do have smartphones may not take
the additional time to scan the code. While the QR would not impede a determined consumer with a
smartphone, consumers who would avoid GMO-containing foods if the information were more easily
available may not gain information they consider valuable to some degree.
196. For example, the standard of “detectable” level of bioengineered food allows foods
containing bioengineered ingredients to be present in food. Id.
197. The intent of the National Bioengineered Food Disclosure law is partially to avoid “a
patchwork state-by-state system that could be confusing to consumers.” Press Release, U.S. Dep’t of
Agric., Establishing the National Bioengineered Food Disclosure Standard (Dec. 20, 2018),
https://www.usda.gov/media/press-releases/2018/12/20/establishing-national-bioengineered-fooddisclosure-standard. [https://perma.cc/G9RT-S8LY]. See also this statement in the Federal Register:
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As is the case in previous causes of action discussed in this section,
consumers would face the challenge of showing that the cause of their alleged
injury is attributable to the ingredient they allege injured them.198 Most likely,
they would have difficulty establishing specific causation or countering the
producer’s argument that they are partially at fault or that their injury is
idiosyncratic rather than potentially common to all consumers.199
Taking all of this into account, it is reasonable to conclude that state law
claims are not likely to cause problems for a food producer, and it appears that
a food producer would have to be irrationally risk-averse to take strenuous steps
to avoid a state law claim. In Part II.B., the focus is on how courts evaluate the
admissibility of expert witness testimony based on animal test data. The
purpose of this section is to assess whether it would make sense for a food
producer to conduct animal tests to defend itself if sued under state laws not
preempted by federal law.
B. Judicial Evaluation of Evidence Based on Animal Studies
This section deals with judicial evaluation of evidence based on animal test
data. As noted in the previous section, toxic tort litigator Lawrence Cetrulo says
that food safety litigation is only in its infancy,200 and food safety litigator Denis
Stearns says that food safety cases are unlikely ever to go forward because of
problems with causation.201 Lucy Meigs et al. note, “The food industry is
relevant with respect to animal testing only as to food additives and
contaminants.”202 As discussed in the previous section, there are almost no such
cases relevant to the subject of food additives. For that reason alone, a rational
food manufacturer would not go to the expense of animal tests to reduce
“This rule is intended to provide a mandatory uniform national standard for disclosure of information
to consumers about the bioengineered status of foods.” National Bioengineered Food Disclosure
Standard, 83 Fed. Reg. 65814, 65814 (Dec. 21, 2018) (codified at 7 C.F.R. 66). This suggests the intent
to preempt state laws. However, the actual language regarding preemption in the National
Bioengineered Food Disclosure statute is not completely clear: “State Food Labeling Standards.—
Notwithstanding section 295 [of the Agricultural Marketing Act of 1946], no State or political
subdivision of a State may directly or indirectly establish under any authority or continue in effect as
to any food in interstate commerce any requirement relating to the labeling or disclosure of whether a
food is bioengineered or was developed or produced using bioengineering for a food that is the subject
of the national bioengineered food disclosure standard under this section that is not identical to the
mandatory disclosure requirement under that standard.” National Bioengineered Food Disclosure
Standard, Pub. L. No. 114-216, § 1, 130 Stat. 834, 837 (2016) (codified at 7 U.S.C. § 1639b(e))
(emphasis added).
198. See supra note 125 and accompanying text.
199. See supra notes 155–56 and accompanying text.
200. CETRULO, supra note 126, at § 39:44.
201. Stearns, supra note 110, at 370–71.
202. Meigs, Smirnova, Rovida, Leist & Hartung, supra note 124, at 302 (emphasis omitted).
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negligible liability exposure risk. This is all the more true since more reliable,
predictive non-animal tests exist203 and since courts are not uniformly or
predictably receptive to animal study-derived data to support safety assessment
evidence. This section examines the basis for judicial skepticism about the
predictive reliability of animal study data to assess the safety of substances to
which consumers are exposed. Because of the lack of food additive cases, this
section relies on consideration of judicial responses in the analogous context of
pharmaceutical drug litigation.
Following enactment of Federal Rule of Evidence 702, the U.S. Supreme
Court decision in Daubert v. Merrell Dow Pharmaceuticals, Inc.,204 and then
the subsequent amendment of Rule 702, the admissibility of a particular
expert’s testimony is not completely predictable because so many case-specific
circumstances must be considered by courts. While Daubert itself dealt with
live animal studies among other research methods, the Supreme Court’s
decision did not directly address the admissibility of expert testimony about
data from such studies.205 In addition to expert testimony based on data derived
from live animal tests, petitioners submitted expert testimony based on data
derived from chemical structural analysis and petitioners’ reanalysis of
respondent’s epidemiological data.206 These submissions were intended to
support petitioners’ claim that respondent’s prescription antinausea drug,
Bendectin, had caused petitioners’ birth defects.207 Both the district court and
the court of appeals rejected the petitioners’ evidence.208 Discussing the
importance of epidemiological evidence and the insufficiency of animal testderived evidence, the district court stated:
The federal courts have held that epidemiological studies
are the most reliable evidence of causation in this area [of
Bendectin litigation]. Accordingly, expert opinion which is not
based on epidemiological evidence is not admissible to
establish causation because it lacks the sufficient foundation
necessary under FRE 703 [general acceptance in the scientific
203. See supra note 44 and accompanying text.
204. 509 U.S. 579 (1993).
205. See id.
206. Id. at 584; “Epidemiology is the study and analysis of the distribution (who, when, and
where), patterns and determinants of health and disease conditions in defined populations.” In re
Johnson & Johnson Talcum Powder Prods. Mktg., Sales Pracs. & Prods. Litig., 509 F. Supp. 3d 116,
130 n.7 (D.N.J. 2020) (citing Michael D. Green, D. Michal Freedman, & Leon Gordis, Reference Guide
on Epidemiology, in FEDERAL JUDICIAL CENTER & NATIONAL RESEARCH COUNCIL OF THE
NATIONAL ACADEMIES, REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 549, 551, 623 (Nat’l Acads.
Press 3d ed. 2011)).
207. Daubert v. Merrell Dow Pharms., Inc., 951 F.2d 1128, 1129 (9th Cir. 1991).
208. Id. at 1131.
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community]. Therefore, expert testimony concluding that
Bendectin causes limb reduction defects which is generally
based upon in vitro studies, chemical structure analyses and
animal studies is insufficient to take the issue to the jury. The
plaintiffs’ experts must be competent to testify that some
epidemiological study or recalculation shows a statistically
significant relationship between the ingestion of Bendectin and
birth defects and that this study forms the basis of their opinion.
In this case, the plaintiffs have failed to . . . provide some
epidemiological evidence to support their claim that Bendectin
is a teratogen.209
Having decided that petitioners lacked admissible evidence with which to
make their case both as to scientifically acceptable methodology and the causal
link to petitioners’ own birth defects, the district court granted summary
judgment to respondent, Merrell Dow Pharmaceuticals.210 The Ninth Circuit
Court of Appeals conducted a de novo review of whether the expert testimony
advanced by the petitioners was based on reliable, accepted scientific
methods.211 The court ultimately agreed with the district court both as to
scientific acceptability of the petitioners’ evidence and as to petitioners’ failure
to establish a causal link between the ingestion of Bendectin and their birth
defects.212
The Supreme Court did not agree with the lower courts regarding centrality
of the scientific community’s acceptance of the research method through which
the proffered evidence had been derived.213 The Court held that Federal Rule of
Evidence 702, enacted after the case law on which the lower courts relied,
included consideration of general scientific acceptance as only one aspect of a
trial court’s decision.214 A trial court must also assess the scientific validity and
reliability of evidence by considering such things as whether the method or
theory used to derive the data offered into evidence had been tested, whether it
had been subjected to peer review and had been published, whether the method
has a high known or potential error rate, and the reliability of the method or
theory as applied to the circumstances of the particular case before the court.215
The case was remanded with directions to consider all of these aspects of the
209. Daubert v. Merrell Dow Pharms., Inc., 727 F. Supp. 570, 575 (S.D. Cal. 1989) (internal
citations omitted) (citing Brock v. Merrell Dow Pharms., 874 F.2d 307, 311–15 (5th Cir. 1989),
modified on reh’g 884 F.2d 166 (5th Cir. 1989)).
210. Id. at 576.
211. Daubert, 951 F.2d at 1130.
212. Id. at 1131.
213. Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993).
214. Id. at 594.
215. Id. at 592–94.
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expert testimony petitioners offered.216 On remand, the Ninth Circuit did not
evaluate the scientific validity of animal test data, finding that petitioners’
experts’ data would not enable them to show that it was more likely than not
that Bendectin had caused the birth defects from which petitioners suffered, as
required by California tort law.217
Although the scientific reliability of animal research-derived data was not
specifically addressed in the Supreme Court’s analysis in Daubert, Daubert
placed responsibility on courts to evaluate expert witness testimony and
evidence, including animal research-derived data. Following its 1993 Daubert
decision, the Supreme Court affirmed in a 1997 decision the importance of
judicial evaluation of the scientific reliability and fitness of expert testimony in
a specific factual context that involved animal testing.218 When reviewing
whether a court had abused its discretion in granting summary judgment based
on refusing to admit evidence reliant on animal testing, the Supreme Court
upheld the court’s rejection of animal test-based evidence, holding that the
court was entitled to deference and had not abused its discretion when it rejected
animal studies involving infant mice that developed alveologenic adenomas
after exposure to massive doses of PCBs administered directly into the lining
of their stomachs.219 The Court noted that plaintiff, Joiner, was an adult human
whose type of cancer differed from that of the infant mice and whose exposure
to PCBs was much less concentrated than was that of the mice.220
The post-Daubert case, Watson v. Dillon Companies, discussed above,221
involved expert witness submissions based on both animal research data and
epidemiological data.222 There was considerable epidemiological evidence
derived from the experience of microwave popcorn plant employees constantly
exposed to diacetyl, and the court’s decision relied heavily on that evidence.223
However, both types of evidence were admitted into evidence, and the court
does not state explicitly that animal test-derived evidence is less scientifically
valid than epidemiological data, though it does acknowledge the limits of such
evidence as applied to humans.224

216.
217.
218.
219.
220.
221.
222.
223.
224.

Id. at 598.
Daubert v. Merrell Dow Pharms., Inc., 43 F.3d 1311, 1320–21 (9th Cir. 1995).
Gen. Elec. Co. v. Joiner, 522 U.S. 136 (1997).
Id. at 144–45.
Id. at 144.
See supra notes 164–71 and accompanying text.
Watson v. Dillon Cos., 797 F. Supp. 2d 1138 (D. Colo. 2011).
Id. at 1154.
Id. at 1153–54.
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Watson v. Dillon Companies is the only case that emerged in a search for
food product litigation that involves animal test-derived data.225 On the other
hand, there are several such cases involving pharmaceuticals in which
consumers claim injury. Perhaps one of the most extensively reasoned cases
involving animal studies is that of Soldo v. Sandoz Pharmaceuticals Corp., in
which plaintiff relied on expert testimony regarding animal tests to allege harm
from one of the defendant’s prescription drugs.226 The court began with a
description of the requirements of Daubert and then drew attention to General
Electric Co. v. Joiner, in which the Court did not disturb the lower court’s
decision that evidence derived from animal studies was inadmissible:
[A] two-step analysis is used to assess the admissibility of the
proffered expert testimony on scientific issues under Rule 702.
First, the expert testimony must be reliable, so that it must be
“scientific,” meaning grounded in the methods and procedures
of science, and must constitute “knowledge,” meaning
something more than subjective belief or unsupported
speculation.
....
In addition, Daubert requires an appropriate “fit” with
respect to the offered opinion and the facts of the case. The
“fit” requirement stems from the instruction of Federal Rule of
Evidence 702 that proffered expert testimony must
“assist . . . the trier of fact.” Under Daubert, scientific
testimony does not assist the trier of fact unless the testimony
has a valid scientific connection to the pertinent inquiry. For
example, there is no fit where there is “simply too great an
analytical gap between the data and the opinion offered,” as
when an expert offers animal studies showing one type of
cancer in mice to establish causation of another type of cancer
in humans.227
At numerous points, the court emphasizes the greater value of
epidemiological research and diminishes the value of animal study data. For
instance, the court includes multiple citations to support its view that
epidemiology is “the primary generally accepted methodology for
demonstrating a causal relation between a chemical compound and a set of

225. This does not mean that such lawsuits have not been filed. Such lawsuits could have settled
or withdrawn, for instance. It is to say only that food litigation that involves cases in which animal testderived data might be submitted did not emerge in a search for such cases.
226. Soldo v. Sandoz Pharms. Corp., 244 F. Supp. 2d 434 (W.D. Pa. 2003).
227. Id. at 526–27 (internal citations omitted) (first citing Daubert v. Merrell Dow Pharms., Inc.,
509 U.S. 579, 590–91 (1993); and then citing Gen. Elec. Co. v. Joiner, 522 U.S. 136 (1997)).
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symptoms or a disease.”228 At another point, the court notes that “studies of
laboratory animals are routinely excluded as irrelevant and unreliable when
proffered as a basis for medical causation testimony.”229 The court cites with
approval Wade-Greaux v. Whitehall Laboratories, Inc.,230 in which data
derived from research on primates was disallowed, with the Wade-Greaux court
“conclud[ing] that the theory of plaintiff’s expert witnesses that they can
directly extrapolate from experimental animal studies without supportive
positive human studies to opine as to causation in humans is one that has an
extraordinarily high rate of error.”231 Indeed, the Soldo court cites multiple
cases in which evidence derived from animal study data was not admissible.232
As to the case at bar, the Soldo court writes, among other criticisms, that
while “plaintiff’s experts recognize that human studies carry greater weight
than animal studies, they provide no explanation for why they give more weight
to an animal study showing alleged effects in the ‘dependent ear margins in
dogs with long hanging ears’ than negative human studies or human studies
demonstrating vasodilation, given that plaintiff is not a dog and does not have
long hanging ears.”233 In other words, the Soldo court first dealt with the matter
of whether animal study research is scientifically sound and then dealt with the
matter of its fitness for deciding the dispute before it, as required post-Daubert.
The Soldo court also dispenses with the argument that regulatory bodies
might have approved marketing of a substance based on animal research data.
The court agreed with the view that “the decisions made in the regulation of
pharmaceutical companies do not necessarily reflect methodologies or
conclusions considered acceptable in the scientific arena and are not necessarily
based on the scientific method. . . . Such regulatory decisions are no better or
worse than the scientific methodology and evidence on which they are
based.”234 Indeed, the court notes, “Plaintiff’s experts have themselves admitted
that FDA decision-making is based on a different standard than tort law-based

228. Id. at 532 (first quoting Conde v. Velsicol Chem. Corp., 804 F. Supp. 972, 1025–26 (S.D.
Ohio 1992), aff’d, 24 F.3d 809 (6th Cir. 1994); then citing Allen v. Pennsylvania Eng’g Corp., 102
F.3d 194, 197 (5th Cir. 1996); then citing Turpin v. Merrell Dow Pharms., 959 F.2d 1349, 1351–56,
1360 (6th Cir. 1992); and then citing In re Breast Implant Litig., 11 F. Supp. 2d 1217, 1224 (D. Colo.
1998)).
229. Soldo, 244 F. Supp. 2d at 546.
230. Wade-Greaux v. Whitehall Lab’ys, Inc., 874 F. Supp. 1441 (D.V.I. 1994), aff’d without op.,
46 F.3d 1120 (3d Cir. 1994).
231. Soldo, 244 F. Supp. 2d at 546–47 (citing Wade-Greaux, 874 F. Supp. at 1480).
232. Id. at 547.
233. Id. at 512.
234. Id. at 513 (citing a report submitted to the Court by Dr. David A. Savitz).
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scientific proof of causation.”235 This may be because of the greater availability
of post-market epidemiological evidence than what is available during premarket safety assessments.
Courts sometimes express multiple concerns about the use of animal
studies. Johnson v. Arkema exemplifies how a court could reject the
admissibility of evidence based on animal testing because of a failure to justify
higher dosing in animals as compared to human exposure and, also,
inappropriate extrapolation to humans.236 Plaintiff alleged that his being
diagnosed with severe restrictive lung disease and pulmonary fibrosis was the
result of two exposures to a chemical used by his employer company,
Arkema.237 Plaintiff’s expert witness relied on two animal studies.238 One
involved exposing nine baboons to the chemical to which plaintiff had been
exposed.239 Although one of the baboons did develop lung impairment, the
impairment arose after the baboon received a much higher exposure than the
plaintiff had experienced.240 The district court rejected the evidence, noting that
plaintiff’s expert witness had not even attempted to address equivalency of the
plaintiff’s exposure and that of the baboons.241 That expert also acknowledged
that “humans are ‘pretty unique.’ ”242 For similar reasons the court rejected
plaintiff’s submission of evidence from a study involving rats.243 The court
emphasized that animal studies have limited utility when addressing questions
of toxicity, stating that studies of the effects of chemicals on animals must “be
carefully qualified in order to have explanatory potential for human beings.”244
Full review of cases alleging harm from pharmaceutical products is well
beyond the scope of this Article, which is focused on animal testing in the
context of novel food ingredients. Nevertheless, even limited review of
pharmaceutical cases reveals many cases in which the court rejects reliance on

235.
236.
237.
238.
239.
240.
241.
242.
243.
244.

Id.
Johnson v. Arkema, 685 F.3d 452 (5th Cir. 2012).
Id. at 457–58.
Id. at 460.
Id. at 463.
Id.
Id.
Id.
Id. at 465–66.
Id. at 466 (quoting Allen v. Pa. Eng’g Corp., 102 F.3d 194, 197 (5th Cir. 1996)).
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animal study data.245 Sometimes courts explicitly specify concerns about
particular aspects of the study’s methodology, such as choice of test species,246

245. See, e.g., Siharath v. Sandoz Pharms. Corp., 131 F. Supp. 2d 1347, 1369 (N.D. Ga. 2001)
(“Plaintiffs also contend that a number of studies conducted on pithed animals (Plaintiffs’ Exs. 18, 19,
20, 21 & 210) show that bromocriptine can cause severe vasoconstriction. Pithed animals have had
their central nervous system obliterated. The pithed animal studies at issue include rats, mice, dogs,
cats and rabbits. . . . Because causation must be based on scientific knowledge allowing for a
reasonable degree of medical certainty rather than mere ‘leaps of faith,’ the Court must conclude that
the animal studies do not assist Plaintiffs in satisfying the requirements of Daubert.”); In re Zoloft
(Sertraline Hydrochloride) Prods. Liab. Litig., 26 F. Supp. 3d 466, 480 (E.D. Pa. 2014) (“Without
evidence that the effects on the serotonin transporter are conserved across species, it is speculative to
draw conclusions about human development from in vitro or even animal studies.”); Blum v. Merrell
Dow Pharms., Inc. 705 A.2d 1314, 1323 (Pa. Super. Ct. 1997) (“Animal studies can also provide
evidence suggestive of causation. However, animal studies without epidemiological studies cannot
prove causation in humans because drugs do not have the same effect on humans as they do on animals;
the doses given to animals in animal studies are very different from those given to humans.”); Lust v.
Merrell Dow Pharms, Inc., 89 F.3d 594, 596, 598 (9th Cir. 1996) (excluding expert opinion partly
based on animal studies reporting fertility drug to be teratogenic in four species of animals); Sorensen
v. Shaklee Corp., 31 F.3d 638, 644, 648 (8th Cir. 1994) (rejecting plaintiff expert opinion based on
animal studies showing sterilant caused teratogenic effects in mice, rats, rabbits, and monkeys).
246. See, e.g., Ellis v. Pneumo Abex Corp., 62 F. Supp. 3d 833, 841 (C.D. Ill. 2014) (questioning
whether mice were appropriate species in a particular cancer study); Bourne ex rel. Bourne v. E.I.
DuPont de Nemours & Co., 189 F. Supp. 2d 482, 496 (S.D.W. Va. 2002) (proffered expert testimony
excluded as neither reliable nor relevant due to extrapolation from high-dosage, single species in vivo
testing and lengthy exposure in vitro testing where no epidemiological studies supported experts’
position, and the relied upon animal studies were far removed from child’s allegations); Kilpatrick v.
Breg, Inc., 613 F.3d 1329, 1338–40 (11th Cir. 2010) (“[The] study at most suggests a connection
between the use of intra-articular pain pumps, bupivacaine, and chondrolysis in rabbit cartilage. This
does not equate to a conclusion of direct causation (or a connection of any degree) between the use of
such pain pumps and chondrolysis in humans. . . . [The expert] also could not explain the possible
differences in dose-response relationship between humans and rabbits. . . . [Regarding] a study of cow
and human cartilage . . . the authors could not state how their test results would transfer when
conducted on a live human subject.”); Turpin v. Merrell Dow Pharms., Inc., 959 F.2d 1349, 1359–60
(6th Cir. 1992) (“The record fails to make clear why the varying doses of Bendectin or doxyalamine
succinate given to the rats, rabbits and in vitro animal cells would permit a jury to conclude that
Bendectin more probably than not causes limb defects in children born to mothers who ingested the
drug at prescribed doses during pregnancy. . . . Several animal studies of cortisone, for example, found
that it causes severe cleft palate birth defects in several animal species, but it does not cause this effect
in humans.”); Tyler ex rel Tyler v. Sterling Drug, Inc., 19 F. Supp. 2d 1239, 1244 (N.D. Okla. 1998)
(excluding evidence based on animals because they were not necessarily reliable evidence of same
reaction in humans); Viterbo v. Dow Chem. Co., 826 F.2d 420, 424 (5th Cir. 1987) (excluding the
evidence where there was only a single animal study of picloram and it showed a link to a disease
completely different than plaintiff’s diseases); Hall v. Baxter Healthcare Corp., 947 F. Supp. 1387,
1410 (D. Or. 1996) (“Extrapolations of animal studies to human beings are generally not considered
reliable in the absence of a scientific explanation of why such extrapolation is warranted.”); E.I.
DuPont De Nemours & Co. v. Castillo ex rel. Castillo, 748 So. 2d 1108, 1120 (Fla. Dist. Ct. App.
2000) (rejecting plaintiffs’ expert’s testimony based solely on rat gavage studies, noting that “experts
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choice of method of exposing animals to the substance,247 and comparability of
animal exposure to human exposure to the same substance.248 As in the case of
Watson v. Dillon Companies, courts value epidemiological data more than
animal studies as scientific evidence to establish causation.249
conceded . . . that the direct extrapolation method they used in their study was new and that they were
unaware of any scientific study that has ever purported to determine a human teratogenic exposure
level in this manner.”).
247. Some judicial decisions in which method of exposure is specifically addressed by the courts
include the following: Bourne ex rel. Bourne, 189 F. Supp. 2d at 498–99 (holding that experts’ reliance
on evidence based on administration of high doses of benomyl directly into the stomachs of rats was
not justified because of lack of “fit” with the facts of the case as alleged and deciding that “the
methodologies of [experts] in concluding that benomyl is a human teratogen [were] unsound”); Gen.
Elec. Co. v. Joiner, 522 U.S. 136, 144 (finding that the District Court did not abuse its discretion in
excluding expert testimony based on “studies involv[ing] infant mice that had developed cancer after
being exposed to PCB’s [since] [t]he infant mice in the studies had had massive doses of PCB’s injected
directly into their peritoneums or stomachs [and] Joiner was an adult human being whose alleged
exposure to PCB’s was far less than the exposure in the animal studies”); Nat’l Bank of Com. (of El
Dorado, Ark.) v. Dow Chem. Co., 965 F. Supp. 1490, 1527 (E.D. Ark. 1996) (finding that the method
of exposure in the animal studies does not fit with the method alleged by plaintiff).
248. For judicial decisions in which courts reject expert reliance on animal test data because of
incomparability of exposure to a substance, either as a general matter or specific to the case, see for
example, Joiner v. Gen. Elec, Co, 864 F. Supp. 1310 (N.D. Ga. 1994) (excluding expert testimony
based on animal studies in part because results from exposure to massive doses of undiluted PCBs
could not be extrapolated to plaintiff whose exposure to PCBs was much less); Bourne ex rel. Bourne,
189 F. Supp. 2d at 498 (excluding experts’ reliance on rat gavage studies and the in vitro tests relied
upon by experts, using injections of high-levels of benomyl, because of lack of fit with the facts of the
case); Gulf S. Insul. v. U.S. Consumer Prod., 701 F.2d 1137, 1146 (5th Cir. 1983) (rejecting evidence
based on animal testing in part because rats in the study “were exposed regularly to much higher doses”
than the average level of exposure in the experiment); In re Rezulin Prods. Liab. Litig., 369 F. Supp.
2d 398, 407 (S.D.N.Y. 2005) (rejecting plaintiffs’ proposed expert testimony in part because “the high
doses often used in animal studies may not correspond to considerably lower concentrations of a drug
or other substance to which humans are in reality exposed”); In re Incretin-Based Therapies Prods.
Liab. Litig., 524 F. Supp. 3d 1007, 1040 (S.D. Cal. 2021) (rejecting evidence based on animal test data
because expert did not consider “whether the dose used in the animal studies upon which he relied,
were similar to those administered to humans”); Sorensen v. Shaklee Corp., 31 F.3d 638, 646 n.12 (8th
Cir. 1994) (rejecting animal test data in this case because of problems with extrapolation to humans
when the dose-response differential between animals and humans, is too great.); Nat’l Bank of Com.
v. Dow Chem. Co., 965 F. Supp. 1490, 1527 (E.D. Ark. 1996) (rejecting animal test data on the ground
that the large doses used in animal tests ordinarily preclude extrapolation to humans), aff’d, 133 F.3d
1132 (8th Cir. 1998).
249. See, e.g., In re Accutane Litig., 191 A.3d 560, 591 (N.J. 2018) (stating that “while animal
studies may be helpful in ‘framing hypotheses,’ the [Federal Judicial Center’s] Reference Manual [on
Scientific Evidence] intimates that such evidence is far less probative in the face of a ‘substantial body
of epidemiologic evidence’ ”); Richardson v. Richardson-Merrell, Inc., 857 F.2d 823, 830 (D.C. Cir.
1988) (“These three types of studies then—chemical, in vitro, and in vivo . . . singly or in combination,
are not capable of proving causation in human beings in the face of the overwhelming body of
contradictory epidemiological evidence.”); Brock v. Merrell Dow Pharms., Inc., 874 F.2d 307, 313
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All of this is not to say that animal test-derived evidence will always be
rejected as lacking scientific validity or fitness with the specific facts of the
case. Indeed, the Federal Judicial Center’s Reference Manual on Scientific
Evidence states the following with specific regard to toxic metal testing: “In
qualitative extrapolation, one can usually rely on the fact that a compound
causing an effect in one mammalian species will cause it in another species.”250
Yet, the Manual goes on to say that care with dosing is necessary for
extrapolation.251
As for in vitro tests, the Manual states the following:
There are short-term in vitro tests for just about every
physiological response and every organ system, such as
perfusion tests and DNA studies, [but] [r]elatively few of these
tests have been validated by replication in many different
laboratories or by comparison with outcomes in animal studies
to determine if they are predictive of whole animal or human
toxicity (footnote omitted). However, these tests, and their

(5th Cir. 1989) (reviewing methodology of various animal studies offered as the basis of expert
testimony and rejecting reliance on animal study data of “questionable applicability to humans” in the
absence of conclusive epidemiologic evidence); In re Abilify (Aripiprazole) Prods. Liab. Litig., 299 F.
Supp. 3d 1291, 1307, 1310 (N.D. Fla. 2018) (finding that an “epidemiological study identifying a
statistically significant association between the use of a drug and a particular adverse effect,
accompanied by a reliable expert opinion that the association is causal, is ‘powerful’ evidence of
general causation” and noting that as to animal studies, “an expert must explain how and why the
studies can be reliably extrapolated” to humans); In re Incretin-Based Therapies Prods. Liab. Litig.,
524 F. Supp. 3d 1007, 1040 (S.D. Cal. 2021) (“[A]nimal studies are not generally admissible where
contrary epidemiological evidence in humans exists.”) (quoting In re Silicone Gel Breast Implants
Prod. Liab. Litig., 318 F. Supp. 2d 879, 891 (C.D. Cal. 2004)); Lee v. Richardson-Merrell, Inc., 772 F.
Supp. 1027, 1030–33 (W.D. Tenn. 1991) (where extensive epidemiological data failed to establish a
causal connection between human ingestion of Bendectin and birth defects, expert testimony reliant
on animal testing and in vitro testing on isolated cells and tissue was not admissible.); In re Agent
Orange Prod. Liab. Litig. 611 F. Supp. 1223, 1250 (E.D.N.Y. 1985) (rejecting plaintiffs’ experts’
opinions based on “studies on the effects of exposure to TCDD on animals and on workers after
industrial accidents” because the experts did not include analysis of “epidemiological studies
conducted on Vietnam Veterans . . . that address[ed] the actual population and amount of exposure
involved in this lawsuit”); Lynch v. Merrell-Nat’l Laboratories, 830 F.2d 1190, 1194 (1st Cir. 1987)
(rejecting in vivo and in vitro animal studies because they could not establish causation in human
beings without any epidemiological data aligning with the animal-based data); Raynor v. Merrell
Pharms. Inc., 104 F.3d 1371, 1375–77 (D.C. Cir. 1997) (rejecting chemical structure analysis, in vivo
animal studies, and in vitro studies in the context of contrary epidemiological evidence and lack of
peer review).
250. Bernard D. Goldstein & Mary Sue Henifin, Reference Guide on Toxicology, in FEDERAL
JUDICIAL CENTER & NATIONAL RESEARCH COUNCIL OF THE NATIONAL ACADEMIES, REFERENCE
MANUAL ON SCIENTIFIC EVIDENCE 633, 646 (Nat’l Acads. Press 3d ed. 2011)).
251. Id. at 645.
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validation, are becoming increasingly important.252
There are indeed many non-animal tests, which will surely displace animalbased testing because of their greater utility in protecting both human safety
and animal welfare.253 This section has shown that animal tests chosen for FDA
approval purposes would not reliably pass judicial muster in post-marketing
tort litigation. A rational food producer would use the most reliable tests
available to produce the safest product, in order to meet FDA obligations and
to protect against a consumer safety lawsuit. Such a producer would be looking
at the science and not simply relying on either product safety assessment
companies, whose incentives may not be fully aligned with the producer’s
objective, or the opinions of FDA reviewers that may not be familiar with the
most current scientific methods available.
PART III. CONSUMER PERSPECTIVES
Thus far, this Article has shown that there is no legal reason a rationally
risk-averse food producer would test a new food ingredient on animals. Part III
considers whether there might be a marketing advantage to testing on animals.
Existing scholarship does not answer such questions as whether consumers
would value a new product more if they assume that its new ingredient is so
novel that it had to be tested on animals or whether consumers, not knowing its
low predictive reliability, generally want assurance of safety testing on animals.
Consumers appear to generally prefer personal care products that have not been

252. Id. at 645–46. The criteria of reliability for an in vitro test include the following: (1) whether
the test is predictive of in vivo outcomes related to the same cell or target organ system, (2) whether
the test has come through a published protocol in which many laboratories used the same in vitro
method on a series of unknown compounds prepared by a reputable organization (such as the National
Institutes of Health (NIH) or the International Agency for Research on Cancer (IARC)) to determine
if the test consistently and accurately measures toxicity, and (3) whether the test has been adopted by
a U.S. or international regulatory body. These criteria of verification and cross-validation of methods
are increasingly met such that reliance on whole animal testing is decreasing. Virtual Interview with
Kathy Guillermo, Senior Vice President, PETA Laboratory Investigations Department, and Jeff
Brown, Science Advisor, PETA Regulatory Testing Department (July 8, 2020). The U.S. Department
of Health and Human Services’ National Toxicology Program Interagency Center for the Evaluation
of Alternative Toxicological Methods (NICEATM) maintains a list of testing methods “that are
accepted by U.S. and international regulatory authorities as replacement, reduction, or refinement
alternatives to required animal tests.” Alternative Methods Accepted by U.S. Agencies, NAT’L
TOXICOLOGY PROGRAM, https://ntp.niehs.nih.gov/whatwestudy/niceatm/accept-methods/index.html
[https://perma.cc/4DJ3-QVYE].
253. See supra notes 43–44.
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tested on animals,254 but perhaps their views differ when the product is ingested
as food.
Both Beyond and Impossible have paid particular attention to consumers,
targeting those attached to meat and trying to replicate exactly the experience
of eating meat. Perhaps some might think that meat-eaters would not care about
ingredient testing on animals. However, meat-eaters might, in fact, care about
whether animal testing, and non-meat-eaters who want to avoid animal testing
may be the ones who provide the most market buoyancy for a plant-based
product. For instance, Joseph Szala, managing director of a restaurant
consultancy, stated with regard to plant-based menu items: “While vegan and
vegetarian patrons will continue to order these kinds of items, they don’t hold
much appeal outside of that.”255 He was discussing this in the context of
restaurants like Del Taco, TGI Friday, and Dunkin’ dropping altogether or
reducing menu space for plant-based options as part of their menu-reduction
strategies.256
Ultimately, consumers’ reasons for eating plant-based meat alternatives and
their perspectives on animal-tested ingredients could be a very important factor
in a food producer’s decision to use or to avoid animal testing. Accordingly, the
history of adoption of meat substitutes, including reasons for use, accessibility,
and preferences for types of protein sources and methods of production are all
relevant to a consideration of plant-based food manufacturers’ decisions. Both
Beyond and Impossible market their products throughout the world,
complicating the picture of consumer perspectives. Part III.A. briefly considers
first the history of meat substitutes, which reveals many reasons other than
animal welfare for their adoption. Since it is not clear that animal welfare was
a primary motivation to develop or consume meat alternatives, perhaps
consumers would not avoid meat alternatives whose ingredients were tested on
animals. To explore questions about consumer receptivity to animal testing to
254. See Postlewhite, supra note 27; see also Global Vegan Cosmetics Industry (2020 to 2027)
– Market Trajectory & Analytics – ResearchAndMarkets.com, BUS. WIRE (May 5, 2021),
https://www.businesswire.com/news/home/20210505005544/en/Global-Vegan-Cosmetics-Industry2020-to-2027—-Market-Trajectory-Analytics—-ResearchAndMarkets.com [https://perma.cc/FMQ8JHWT] (“The global market for Vegan Cosmetics estimated at US $15.1 Billion in the year 2020, is
projected to reach a revised size of US $21.4 Billion by 2027, growing at a CAGR of 5.1% over the
analysis period 2020–2027.”).
255. Leslie Patton & Deena Shanker, Beyond Meat Loses Some Early Restaurant Fans As Others
Double Down, BLOOMBERG (Feb. 3, 2022), https://www.bloomberg.com/news/articles/2022-0203/some-beyond-meat-early-adopters-move-on-as-others-double-down
[https://perma.cc/Y4KYZL7F].
256. Id. (noting a phenomenon of restaurants first adopting and later dropping plant-based food
items and, quoting Szala, “Smaller menus mean quicker and more accurate ordering, preparing,
delivering.”).
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assess toxicity and allergenicity of novel food ingredients, the author and
Professor Adam Feltz conducted a nationally representative survey of
American consumers’ views. Some of those survey results are discussed in
Part III.B.
A. History of Meat Alternative Usage
The use of processed plant foods explicitly identified as meat substitutes
has a long history. That history reflects impacts due to the timing of
identification and development of appropriate sources to replace the nutritional
content of meat, changing technologies to produce alternatives to meat, and
considerations of consumer receptivity to different types of meat alternatives.257
Asia has a longer tradition of foods known now to be good sources of protein
and as nutritionally adequate meat replacements. The first known written
mention of such a food was in 965 CE in China, when the use of soybeans was
facilitated by its easy production methods and encouraged as a frugality
measure.258 Called “mock lamb chops,” this substitution may have had more to
do with the malleability of tofu to appear as different food products than to the
deliberate search for a protein source; the term “protein” was first used in the
scientific literature in 1838.259 Soy is now accepted as a good but somewhat
problematic protein source because of its potential to provoke an allergic
response.260 Processed in various ways and readily available in grocery stores
in the United States, soy continues as a commonly used protein alternative to
animal-based meat products. Indeed, it commands an increasing market share
of protein-supplying foods.261 MarketResearch.com reported in April 2021 that
257. Jiang He, Natasha Marie Evans, Huaizhi Liu & Suqin Shao, A Review of Research on PlantBased Meat Alternatives: Driving Forces, History, Manufacturing, and Consumer Attitudes, 19
COMPREHENSIVE REVS. FOOD SCI. & FOOD SAFETY 2639 (2020).
258. SHURTLEFF & AOYAGI, supra note 1, at 5.
259. Daniel E. Koshland, Protein, BRITANNICA, https://www.britannica.com/science/protein
[https://perma.cc/LP7R-ZD8A].
260. Food
Allergies,
U.S.
FOOD
&
DRUG
ADMIN.
(Jan.
31,
2022),
https://www.fda.gov/food/food-labeling-nutrition/food-allergies
[https://perma.cc/82JC-VCW5]
(listing the 8 major food allergens recognized by the United States—milk, eggs, fish, shellfish, tree
nuts, peanuts, wheat, and soybean—which require allergen labeling, and noting that effective Jan. 1,
2023, sesame will be added to this list).
261. See Suzanne Hamlin, Do You Speak Tofu or Miso Yet?, N.Y. TIMES (Aug. 9, 1995),
https://www.nytimes.com/1995/08/09/style/do-you-speak-tofu-or-miso-yet.html
[https://perma.cc/EAR3-RXCA] (“At the turn of the century, there were two tofu suppliers in the
United States. Today there are more than 200 tofu manufacturers . . . and tofu can be found in nearly
every supermarket.”); Audrey Enjoi, Move Over, Beyond Burgers, Tofu is Going Mainstream,
LIVEKINDLY (June 22, 2020), https://www.livekindly.co/beyond-burgers-tofu-going-mainstream/
[https://perma.cc/YVG4-Q9HY] (“Sales of tofu have skyrocketed in the US amidst the coronavirus
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“[i]n 2020, the global Tofu market size was US$ 2244.29 million and it will
reach US$ 4629.25 million in 2027, growing at CAGR [Compound Annual
Growth Rate] of 10.75% between 2021 and 2027.”262
Soy may be accelerating in popularity and variety, but it is certainly not the
only plant-based meat substitute. Wheat gluten also has considerable longevity
as a meat alternative. The first known reference to wheat gluten as a main
ingredient in a meat alternative was in 1301 in China.263 Like soy products,
wheat gluten continues as an important ingredient in many plant-based meat
alternatives, but like soy, some find it problematic because of physiological
sensitivity. According to the Food Allergy Research & Education organization,
soy and wheat rank among the top nine major food allergens responsible for
most of the serious food allergy reactions in the US.264
Although soy-based and wheat gluten-based meat substitutes remain the
most prevalent, the number and type of meat substitutes have grown steadily.265
Nut-based meat alternatives have been available in the United States since the
late 1800s, and a high protein fungus, Fusarium venenatum, was introduced to
the market as “Quorn” in 1994.266 Processed pea protein is perhaps the most
recent addition to the menu.267
High market growth of all meat substitutes, not just soy and wheat-based
alternatives, is predicted due to increasing demand for healthier protein sources

pandemic. . . . According to data from global market research firm Neilsen, tofu sales increased by
66.7 percent during the four-week period ending on March 28. This is compared to the same time
period in 2019. Sales of tofu were up by 32.8 percent in May.”).
262. QYResearch Group, Global Tofu Market Research Report 2021 (Description),
MARKETRESEARCH
(Apr.
2021)
https://www.marketresearch.com/QYResearch-Groupv3531/Global-Tofu-Research-14411396/ [https://perma.cc/6P39-MQAJ].
263. SHURTLEFF & AOYAGI, supra note 1, at 5.
264. Food Allergy Essentials: Common Allergens, FOOD ALLERGY RSCH. & EDUC.,
https://www.foodallergy.org/living-food-allergies/food-allergy-essentials/common-allergens
[https://perma.cc/B34D-TG76].
265. Jeff Kart, People Buying More Alternative Meat, Expected To Consume Less Real Meat
Through 2025, FORBES (July 17, 2020), https://www.forbes.com/sites/jeffkart/2020/07/17/peoplebuying-more-alternative-meat-expected-to-consume-less-real-meat-through-2025/?sh=4cc280361a06
[https://perma.cc/7TR8-62Z5]; see also SHURTLEFF & AOYAGI, supra note 1, at 9.
266. Matt Connolly, Timeline: A Short and Sweet History of Fake Meat, MOTHER JONES (Dec.
2013),
https://www.motherjones.com/environment/2013/12/history-fake-meat/
[https://perma.cc/34CT-5AGG].
267. Commercial processing of peas to produce a concentrated protein for use in meat substitutes
appears to have started in 2014 with its development by Puris Foods. Christopher Doering, Once a
Sidekick in Food, the Pea Finds Itself the Star of the Show, FOODDIVE (Jan. 23, 2020),
https://www.fooddive.com/news/once-a-sidekick-in-food-the-pea-finds-itself-the-star-of-theshow/570224/ [https://perma.cc/C8WV-V7Z4].
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than animal meat and increasing interest in plant-based diets.268 Citing research
reported in 2010, Jiang He et al. state that vegetarianism has increased due to
religious beliefs, concern about animal rights, health benefits from consuming
less meat, and personal preferences, such that the demand for plant-based meat
alternatives has increased.269 Predicted growth is also partially due to greater
awareness of the climate impacts of methane gas from agricultural animals,
notably cows.270 It is also associated with predicted and real meat shortages due
to supply chain problems during the Covid-19 pandemic.271 In addition to
environmental and economic concerns, other prominent, overlapping drivers of
plant-based substitute consumption are increasing awareness of the human
health problems associated with over-consumption of meat and increasing
responsiveness to the significant harms to animals in the production of animal
products.
In the United States, religious ideas were also a factor in the development
of meat alternatives because of the impact of Dr. John Harvey Kellogg, a
Seventh Day Adventist. Seventh Day Adventists are encouraged to avoid meat
from animals identified as “unclean” in the Bible.272 Dr. Kellogg was also
influenced by his belief that “[an] increase of population would ultimately lead

268. Meat Substitutes Market Size, Share & COVID-19 Impact Analysis, By Source (Soy-based
Ingredients, Wheat-Based Ingredients, Other Grain-based Ingredients, and Textured Vegetable
Proteins), By Distribution Channel (Mass Merchandisers, Specialty Stores, Online Retail, Other Retail
Channels, and Food Service), and Regional Forecasts: 2021-2029 (Summary), FORTUNE BUS.
INSIGHTS (Aug. 2022), https://www.fortunebusinessinsights.com/industry-reports/meat-substitutesmarket-100239 [https://perma.cc/6E63-4FE9] [hereinafter Meat Substitutes Market Size].
269. He, Evans, Liu & Shao, supra note 257 (citing Leahy Eimear, Sen Lyons & Richard Tol,
An Estimate of the Number of Vegetarians in the World (Econ. & Soc. Rsch. Inst., Working Paper No.
340, 2010)).
270. UN ENVIRONMENT PROGRAMME, GLOBAL METHANE ASSESSMENT: BENEFITS AND
COSTS OF MITIGATING METHANE EMISSIONS 25 (2021) (“Emissions from livestock are the largest
source of agricultural emissions with enteric fermentation the dominant process and cattle the dominant
animal causing the emissions.”); see also Meat Substitutes Market Size, supra note 268.
271. See, e.g., Alexandra Sternlicht, Alternative Meat Sales Soar Amid Pandemic, FORBES (May
4, 2020), https://www.forbes.com/sites/alexandrasternlicht/2020/05/04/alternative-meat-sales-soaramid-pandemic/?sh=d5e8261edfd7 [https://perma.cc/EEU5-Q8P9] (citing and describing Nielsen’s
[consumer spending] report that meat alternative sales increased 255% in the last week of March 2020,
outpacing the growth of meat sales, which increased 53% over the same period); Amelia Nierenberg,
Plant-Based “Meats” Catch On in the Pandemic, N.Y. TIMES (May 22, 2020),
https://www.nytimes.com/2020/05/22/dining/plant-based-meats-coronavirus.html;
[https://perma.cc/Q3AW-8NRC]; Jacob Bunge & Heather Haddon, Coronavirus Meat Shortages Have
Plant-Based Food Makers’ Mouths Watering, WALL ST. J. (May 13, 2020),
https://www.wsj.com/articles/coronavirus-meat-shortages-have-plant-based-food-makers-mouthswatering-11589371206 [https://perma.cc/SET5-A49P].
272. Meat Laws, SEVENTH-DAY ADVENTIST DIET, https://www.seventhdayadventistdiet.com/
meat-laws/ [https://perma.cc/TR9A-FF9W].
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to an increase in the price of foodstuffs and particularly of meats, and possibly
a scarcity of meats.”273 Kellogg, a scientist, invented flaked cereals as a
substitute for animal product-based breakfast foods and developed a number of
meat substitutes derived from nuts.274 He believed nuts to be “unquestionably
the vegetable analogue of meat and other animal foods, not only containing all
the food elements to be found in animal products, but in finer and more
digestible form, more delicately flavored, and wholly free from deleterious
elements which abound in meat.”275 Vegetarianism, as promoted by Dr.
Kellogg and the business he developed with his brother, was a matter of
supporting health with “clean” foods in both religious and practical senses of
that word.
For quite some time in the United States, there have been people who have
chosen vegetarian and vegan diets because of regard for animals.276 The term
“ethical veganism” captures this perspective, which appears to have been
heavily influenced initially by philosopher Peter Singer’s 1975 book, Animal
Liberation.277 His book describes the suffering of animals in western
agribusinesses and encourages strong consciousness of individual
responsibility to resist participation in animal cruelty through consumer
choices.278 While plant-based meat substitutes would appeal to such consumers
generally, it is not clear that a burger reminiscent of bleeding meat would be a
particular draw, and they are not the target consumer for either Beyond or
Impossible.
Meat substitutes vary as to their health-conferring properties and extent of
processing. As new technologies have emerged, variance among meat
alternatives has increased. At one end of the processing spectrum is a product
like Butler soy curls, which are made of one ingredient—organic non-GMO
soybeans—and made with minimal processing to enable meat-like cooking

273. SHURTLEFF & AOYAGI, supra note 1, at 6 (quoting JOHN. H. KELLOGG, THE NATURAL
DIET OF MAN 334–36 (1923)).
274. Id.
275. Id. (quoting JOHN. H. KELLOGG, MODERN MEDICINE AND BACTERIOLOGICAL REVIEW
220–23 (1986)).
276. See, e.g., KAREN IACOBBO & MICHAEL IACOBBO, VEGETARIAN AMERICA: A HISTORY 1
(2004) (“Vegetarian America has existed since at least the 1700s. Practiced by small pools of people
during the eighteenth century, the meandering stream of vegetarianism would burst forth like Niagara
Falls by the late twentieth century.”). Citing Benjamin Franklin as an example, Iacobbo and Iacobbo
point to ethical concerns about the treatment of animals as a basis for avoiding consumption of products
made from their bodies. Id. at 1–2.
277. See generally PETER SINGER, ANIMAL LIBERATION (1975).
278. Id. at 166–67 (describing vegetarianism as a boycott of cruelly produced animal products).
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applications.279 At the opposite end are the Beyond and Impossible burgers,
which are highly processed and contain much higher amounts of sodium and
saturated fats than desirable from a nutritional point of view.280 Accordingly,
they are not ideal replacements for meat products from the standpoint of human
health and might appropriately be seen more as a fast-food equivalent than a
staple in the diet.281
Driven by technological advancements necessary to produce these
facsimiles of meat, these plant-based burgers may be responsive to consumer
preference for meat-like attributes, particularly among those attached to the
experience of eating meat, as Beyond and Impossible predict. Yet, consumers
attached to meat itself might ultimately be more likely to eat animal flesh
cultured from the cells of animal tissue (sometimes referred to as “clean
meat”).282 The results of research published by Christopher Bryant and others
in 2019 comparing consumer attitudes to plant-based meat and clean meat
suggest that meat attachment correlates more positively with clean meat and
less positively with plant-based meats.283 When reporting their results, Bryant
et al. state the following:
In the USA, we find that meat-eaters are most likely to
express interest in purchasing clean meat . . . . We also found
that meat attachment predicted lower purchase likelihood of
plant-based meat, but not of clean meat. This implies that
plant-based and clean meat could cater to different markets in
the US: whilst plant-based meats may be appealing to those
low in meat attachment, clean meat may play a crucial role in
279. How
Are
Soy
Curls
Made?,
BUTLER
FOODS
https://www.butlerfoods.com/soycurlsmade.html#:~:text=Soy%20Curls%E2%84%A2%20are%20dri
ed,chemicals%2C%20additives%2C%20or%20preservatives [https://perma.cc/T2MB-DWMC]; see
also Kelly Clarke, The Soy Curl Was Born in Oregon, PORTLAND MONTHLY (Aug. 17, 2017),
https://www.pdxmonthly.com/health-and-wellness/2017/08/the-soy-curl-was-born-in-oregon
[https://perma.cc/CR6R-LUW3] (“Butler Foods owner Dan Butler and his small crew have produced
the all-natural curls for nearly 20 years—soaking, cooking, and stirring organic soybeans in spring
water, then letting them slowly dry out.”).
280. Emily Gelsomin, Impossible and Beyond: How Healthy are these Meatless Burgers?,
HARV.
HEALTH
PUBL’G:
HARV.
MED.
SCH.
(Jan.
24,
2022),
https://www.health.harvard.edu/blog/impossible-and-beyond-how-healthy-are-these-meatlessburgers-2019081517448 [https://perma.cc/8FYX-HEHM] (discussing high levels of sodium and
saturated fat in both burgers and recommending black bean burgers as significantly healthier).
281. Id.
282. Christopher Bryant, Keri Szejda, Nishant Parekh, Varun Deshpande & Brian Tse, A Survey
of Consumer Perceptions of Plant-Based and Clean Meat in the USA, India, and China, 3 FRONT.
SUSTAIN. FOOD SYST., Feb. 2019, at 1, 2, 8 https://doi.org/10.3389/fsufs.2019.00011
[https://perma.cc/H28Q-TTXS] (defining “clean meat” as meat “produced by culturing animal cells in
a suitable medium”).
283. Id. at 8.
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displacing demand for conventional meat amongst those who
do not find plant-based meat appealing.284
Perhaps not surprisingly, vegetarians, vegans, and pescatarians have lower
meat attachment and would be more apt to select plant-based meats than clean
meat replacements for actual meat.285 If those consumers also care about testing
on animals,286 their willingness to consume plant-based burgers might lead
them to choose plant-based meat alternatives that do not involve animal testing.
The next section examines that question: the extent of consumer acceptance or
rejection of animal testing on food ingredients in plant-based foods.
B. Results of Research on Consumer Attitudes
In late January of 2022, Professor Adam Feltz and I conducted a random,
demographically representative survey designed to better understand if
consumers think that animal testing of food ingredients is beneficial or
necessary and the extent to which they believe such animal testing is required
by the FDA.287 We asked questions about such things as extent of meat
consumption, preference for personal care products not tested on animals,
knowledge about animal testing techniques, and whether animal testing of an
ingredient in a favorite food product would negatively influence their decision
to purchase it in the future. We chose “burgers” as the plant-based food because
we predicted that most of the survey respondents would consume burgers of
some type. In fact, more than 98% of respondents do consume burgers of some
type. The survey required respondents to rate their willingness to consume
burgers differing as to animal testing for purposes of allergenicity or toxicity
assessments and whether it was the supplier or the manufacturer that engaged
in the animal testing.288 Here is a representative block of burger options
provided to respondents:
Burger A is a plant-based burger. It has a new flavoring
284. Id. (noting that their research replicates the finding of Matti Wilks & Clive J.C. Phillips,
Attitudes to in Vitro Meat: A Survey of Potential Consumers in the United States, 12 PLOS ONE, Jan.
2017, at 1, 10–11 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171904
[https://perma.cc/AU9A-L349]).
285. Id. at 7.
286. This might be somewhat difficult to assess because survey data do not necessarily reveal
whether consumers are more influenced by health and environmental concerns rather than by animal
welfare concerns.
287. We used three pilot studies to determine the correct sample size and survey design. We
doubled the sample size to 633 “clean” surveys. We are preparing an article describing the study in
more detail and exploring its implications. In the meantime, information about the research
methodology is available upon request from the author of this Article.
288. More detailed description of the methodology, specific questions, and results is forthcoming
in a separate article.
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ingredient that the Burger A Company toxicity-tested on
animals. Burger A Company used painful methods. All of the
animals used in the testing were killed at the end of the
experiment.
Burger B is a plant-based burger. It has a new flavoring
ingredient that the Burger B Company toxicity-tested on
animals. Burger B Company used non-invasive, relatively
pain-free methods. All of the animals used in the testing were
placed in an animal sanctuary after the testing was complete.
Burger C is a plant-based burger. Its new flavoring
ingredients were not tested on animals at all because Burger C
Company used alternative methods of assessing safety.
All respondents rated their willingness to consume each burger by selecting
among options running from “Would not consume at all” to “Extremely likely.”
If a respondent “would not consume” any of the burgers, the respondent was
asked why.
Respondents were asked in separate blocks of questions (similar to the
block of options above) about burgers whose flavoring ingredients were tested
for potential allergenicity and/or tested by suppliers instead of the
manufacturer. In the end, each respondent made choices among three burger
options in four different contexts: manufacturer testing for toxicity,
manufacturer testing for allergenicity, supplier testing for toxicity, and supplier
testing for allergenicity. At the start, respondents randomly did or did not
receive information about animal testing techniques. Also, half the respondents
received information that the FDA does not require animal testing, while
answering the “burger” questions; half received that information after
answering the burger questions and were asked to re-rate their burger ratings in
light of that information.
In all of those iterations, respondents consistently rejected animal testing,
including animal testing that involved only pain-free methods and placement of
the test animals in sanctuaries. Respondents indicated the strongest preference
for the burgers not tested on animals at all, followed at notable distance by
burgers with ingredients tested painlessly on animals, and the least preference
for burgers tested on animals using painful methods. The presence of any type
of animal testing had a strongly negative effect on respondents’ ratings.289
289. 46.15% of respondents indicated that they would not consume at all the burger whose
ingredients were toxicity-tested using painful methods while 23.06% would not consume the burger
tested with relatively pain-free methods. Only 11.15% indicated that they would not consume the
burger that was not subject to an animal test. Among those who did not indicate that they would avoid
the product altogether, the mean proclivities to consume for the burgers tested on animals for toxicity
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Respondent willingness to consume burgers with ingredients tested with
painful methods was not significantly less when respondents had been told that
the FDA does not require animal testing, prior to their rating of the different
burgers. The data suggest that respondents just generally did not like the idea
of animal-tested ingredients.
Preference for plant-based burgers that were not tested on animals is
consistent with 68.72% of respondents in this survey reporting that, whenever
possible, they purchase personal care items that have not been tested on animals
and with 57.91% of respondents indicating that if they learned that ingredients
in a favorite product had been tested on animals, they would be less inclined to
purchase that product. Moreover, respondents thought that products containing
animal-tested ingredients should be labeled as such, whether the testing is done
by the manufacturer (79.78%) or an ingredient supplier (80.57%).
It is important to note that this survey involved a random, demographically
representative group of respondents consisting predominantly of consumers
who regularly eat meat, as is true of the general population. Indeed, based on
responses to the meat consumption questions included in the survey, only 2%
of respondents were vegetarians or vegans. It would be a mistake to think that
only vegan or vegetarian consumers care about animal tested consumer
products. Nevertheless, because the study was focused on plant-based burgers,
it is difficult to conclude without further research whether survey respondents
objected to animal testing only as to plant-based burgers or in general. Further,
important aspects of consumer decision making were held constant. If burgers
varied as to cost, flavor, convenience, and inclusion of animal-tested
ingredients, more information would emerge as to the relative value of each of
those characteristics. It is not possible to predict with these data how important
animal testing would be in comparison to these other consumer decisional
criteria. More research would clarify this situation, but given the strength of
these survey results, it is possible to say that consumers do care about animal
testing even if we cannot say to what degree they would prioritize its avoidance
in comparison to other criteria, such as cost, convenience, and flavor.

using painful and non-painful methods were 2.67 and 2.99 respectively, while that for the burger not
tested on animals was 3.71, where 1 is “extremely unlikely” and 5 is “extremely likely.” The responses
with regards to the burgers tested for allergenicity using animal tests were similar: 44.41% would not
consume at all the burger tested using painful methods and 25.13% would not consume the burger
tested using pain-free methods, while only 12.98% would avoid the burger not tested on animals.
Ratings among those who would not avoid the burgers altogether were 2.72, 3.08, and 3.72
respectively, for the burgers tested for allergenicity using painful methods, pain-free methods, and
without animal testing altogether.
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CONCLUSION
This Article used Impossible’s decision to test on animals as an organizing
structure for considering reasons a manufacturer might test on animals. It is an
important and timely issue as more bioengineered ingredients are being
developed for inclusion in alternatives to animal-based products.290
Impossible’s decision is timely also in relation to recent lawsuits against the
FDA, which validated the FDA’s handling of GRAS assessments291 and the fact
that the Redbook guidelines are only guidelines.292 Having considered federal
regulation, food safety litigation, and judicial evaluations of data derived from
animal testing, it is straightforward to conclude that there is no legal necessity
or legal value to be gained from testing on animals. To the extent animal testing
is used instead of more predictably reliable non-animal methods, both consumer
safety and animal welfare suffer. Judicial concerns about extrapolation from
animal study data to humans should be the concerns of all decision makers in
this context, especially when test animals are exposed to massive doses of
ingredients humans would not consume at similar levels.
It is not possible to know how much animal testing is actually occurring
because manufacturers need not seek FDA review of their GRAS
assessments.293 Among the reasons a manufacturer might test on animals are
ignorance that superior non-animal methods exist, unquestioning dependence
on product safety assessment companies that maintain animal laboratories
without being equipped to offer the most sophisticated and reliable safety
testing methods, advantages of faster FDA processing if the manufacturer treats
FDA sample animal tests as safe harbor rules, or use as a marketing strategy to
claim that an ingredient is so unique and innovative that its safety requires
animal testing.
The last reason devalues consumers’ desire for reliable predicters of food
ingredient safety and greatly misjudges consumer attitudes about animal
welfare and animal testing. The fact that the “cruelty-free” personal care
product market has remained quite strong should suggest to a manufacturer of
any product that testing on animals might well risk a negative consumer
response.294 The survey described in Part III.B. reveals that even a large
290. See, e.g., Aryn Baker, The Next Hottest Alternative Milk Comes from Microbes, TIME (July
22, 2022), https://time.com/6199318/milk-alternatives-microbes-perfect-day/ [https://perma.cc/865SLLNP]; Maija Palmer, The Big Idea: Milking Microbes Instead of Cows, SIFTED (June 18, 2021),
https://sifted.eu/articles/milking-microbes-imagindairy/#:~:text=Imagindairy%20uses%20a%20
technique%20called,that%20make%20up%20cow’s%20milk [https://perma.cc/6GMJ-Y5AU].
291. E.g., Ctr. for Food Safety v. Becerra, 565 F. Supp. 3d 519, 543 (S.D.N.Y. 2021).
292. Ctr. for Food Safety v. U.S. Food & Drug Admin., 854 F. App’x. 865 (9th Cir. 2021).
293. See supra Part I.A.
294. See supra note 254 and accompanying text.

BRYANT_21NOV22 (DO NOT DELETE)

2022]

NOVEL FOOD INGREDIENTS

159

majority of those who consume meat would choose a burger that does not
involve animal-tested ingredients, just as a majority would choose personal care
products that are not tested on animals. It is simply wrong to assume that meat
consumers do not care about animals as a general matter. In the case of a plantbased burger, the manufacturer that tests on animals not only misses the
opportunity to use the most reliable safety assessment methods, but it also
misses the opportunity to truthfully claim a trifecta of animal protection:
wildlife, cows, and laboratory animals. A plant-based food manufacturer that
tests on animals is in the position of a film company that must say, “Only a few
animals were harmed in the making of this film,” instead of, “No animals were
harmed . . . .”
Chief among the changes necessary to better protect humans and animals is
revision of FDA guidelines and procedures. If the state of the science supports
major food manufacturers deciding not to test new ingredients on animals and
legislators proposing that pharmaceutical companies have the option of
bypassing animal testing before advancing to human clinical trials, the state of
the science supports the FDA’s adoption of the presumption that non-animal
safety assessments should be the basis of manufacturers’ GRAS assessments
and their pursuit of “no questions” letters. Considering the “3Rs” principle
embedded in the Animal Welfare Act295 and the risks posed to consumers by
use of less reliable safety assessments, manufacturers should have to seek
advance permission to use animal testing, while non-animal safety assessments
should not need prior FDA approval. FDA regulations already allow nonanimal testing. This is a shift in priority of assessment methods already allowed
by the FDA, a shift that would respect the public’s desire for both reliable safety
assessment of food ingredients and protection of animals. There is ample
justification to require food manufacturers relying on the least up-to-date safety
assessment methodology to explain why animal testing is necessary for their
novel food ingredient.
Increasing availability of reliable non-animal safety assessment tools can
occur if the FDA puts in place the proposed presumption of non-animal safety
assessment methods for novel food ingredients; surely, product safety
assessment companies would ramp up to meet the demands of that new
regulatory requirement. However, change may be generated more quickly by
manufacturers’ insistence that such assessment tools be used for their novel
food ingredients. If enough manufacturers take seriously consumer rejection of
animal testing, manufacturers will more likely press for use of non-animal
testing. At present, though, consumers do not yet realize that new food
ingredients are tested on animals. 66.1% of survey respondents did not know
295. See 7 U.S.C. § 2143(e).
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that new food ingredients are ever tested on animals, and 57.6% stated that they
were surprised by that information.296
Therein lies another critical issue—lack of consumer awareness.
Manufacturers need not consider what consumers would reject if consumers do
not have easy access to the knowledge necessary to defend their values. And
consumers cannot knowledgeably speak with the dollars they spend if they
cannot differentiate products in accordance with the values they hold. It is
important that they know. Yet, certainly, food manufacturers that test on
animals will not be inclined to advertise the fact. While some food
manufacturers that do not test on animals do, in fact, let consumers know, others
might not be inclined to label their products as “cruelty-free” until consumers
are likely to know that food ingredients in their category of food could be tested
on animals. In this case of plant-based food, consumers might mistakenly
believe that all plant-based foods would be cruelty-free and consider it a
competitor gimmick to label such a product as “cruelty-free.”
This is where food safety organizations and animal protection organizations
can work toward increasing food manufacturers’ utilization of non-animal tests
to increase consumer safety as well as animal protection. They can work for the
replacement of animal tests with non-animal tests, and they can educate the
public about products that contain animal-tested ingredients. If they do not,
consumers will be unable to further their interests in consumer safety and
avoidance of animal tested products. Despite the obvious value of informing
the public of animal-tested food ingredients and supporting non-animal-tested
alternatives, there is significant silence on this in the context of Impossible’s
testing on animals. Several searches for statements by antivivisection and
animal protection organizations came up empty; it appears that PETA has stood
alone on this issue.
The Center for Food Safety’s argument in Center for Food Safety v. U.S.
FDA297 that the FDA should have required Impossible to do more animal
testing298 rather than different testing suggests that it is not aware of the lesser

296. Half of the respondents were asked to respond to T/F questions regarding their knowledge
of common animal test methods and whether the FDA requires animal testing. Of those who got the
T/F questions and answered that they “did not know” if the FDA requires animal testing of novel food
ingredients, 66.1% responded that they were surprised to learn that the FDA does not require such
testing. See supra Part III.B. for more details about this survey.
297. 854 F. App’x. 865 (9th Cir. 2021).
298. Press Release, Center for Food Safety, Lawsuit Challenging FDA Approval of Novel
Genetically Engineered Color Additive That Makes Impossible Burger “Bleed” Moves Forward (Jan.
29,
2021),
https://www.centerforfoodsafety.org/press-releases/6256/lawsuit-challenging-fdaapproval-of-novel-genetically-engineered-color-additive-that-makes-impossible-burger-bleed-movesforward [https://perma.cc/8R6T-Y3TD].
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reliability of animal testing as a predictor of human safety risk, despite the fact
that consumer safety is core to their mission.299 Similarly, the silence of
antivivisection and nonprofit animal protection organizations other than PETA
about Impossible’s animal testing is mysterious, given their missions. It seems
unlikely that this is attributable to lack of awareness. Moreover, access to the
basic information, including the tests actually used, is not difficult when another
organization has done the work of collecting the correspondence between the
FDA and Impossible.300 Even a brief look at the FDA’s guidelines reveals that
animal testing is not required. One would think that many antivivisection
organizations would have spoken against this use of animals, just as one would
think that animal-respecting investors would do the legal investigation
sufficient to discover that testing novel food ingredients on animals is not
required.
It is also reasonable to expect that nonprofit organizations specifically and
deeply invested in reducing consumption of farmed animals would take a stand
against unnecessarily inflicting severe suffering and death on laboratory
animals, particularly when the marketplace is full of meat alternatives that do
not include ingredients that have been tested on animals. Lack of necessity to
inflict severe suffering on animals is the hallmark and baseline of every state
anticruelty statute in the country.301 Yet animal protection organizations did not
support this principle in this case in which it was totally unnecessary to subject
laboratory animals to terrible suffering and death by a company pursuing the
production of “bleeding” hamburger equivalents.
It is difficult to know what is animating this, but perhaps this is an example
of what legal scholar Gary Francione considers to be a damaging “single-issue”

299. About
Center
for
Food
Safety,
CTR.
FOR
FOOD
SAFETY,
https://www.centerforfoodsafety.org/about-us
[https://perma.cc/Q7ZG-9P7Y]
(“Through
groundbreaking legal, scientific, and grassroots action, we protect and promote your right to safe food
and the environment.”).
300. In addition to PETA’s work on this issue, Friends of the Earth has posted documents related
to the FDA’s approval of Impossible’s GE heme, which it obtained through Freedom of Information
Act requests. Email from Gary L. Yingling, Senior Couns., Morgan, Lewis &Bockius LLP, to Lauren
Brookmire, Consumer Safety Officer, U.S. Food & Drug Admin., (May 29, 2015) https://foe.org/wpcontent/uploads/2017/08/072717_Impossible_Burger_FOIA_documents.pdf
[https://perma.cc/NBN2-4E33].
301. “The legislatures of all 50 states and the District of Columbia have enacted anticruelty
statutes that purport to protect animals against ‘unnecessary suffering,’ ‘unjustified suffering,’ or ‘cruel
mistreatment.’ ” Darian M. Ibrahim, The Anticruelty Statute: A Study in Animal Welfare, 1 J. ANIMAL
L. & ETHICS 175, 179 (2006).
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focus on some animals that inadvertently harms other animals along the way.302
In this case, it is single-minded focus on the reduction of the suffering of farmed
animals in such a way that other animals, even those directly harmed in the
pursuit of that single issue, are deemed less important. There was no necessity
for investors identifying themselves as animal-protective or animal protection
organizations to throw laboratory animals under one of the many buses rolling
toward a plant-based future. Indeed, protecting the least charismatic of animals
when advocating for other animals is surely important for increasing respect for
all animals. Before supporting or investing in the development of one product
or another, it is important for organizations that identify with the value of
protecting animals to consider whether animals were or will be harmed at some
point in product development and to do the research to know whether actual
necessity exists. It is important, also, that such entities seek to prevent the use
of animal tests in the development of new products. The serious harms done to
animals by subjecting them to testing are all the more unconscionable because
use of such tests delays the application and further refinement of reliable nonanimal tests that actually exist and confer greatest benefit to consumers.

302. Gary L. Francione, Single Issue Campaigns in Human & Nonhuman Contexts, ANIMAL
RIGHTS:
THE
ABOLITIONIST
APPROACH:
BLOG
(Feb.
1,
2010),
https://www.abolitionistapproach.com/single-issue-campaigns-and-in-human-nonhuman-contexts/
[https://perma.cc/M75G-GFQE].

